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Abstract 
The ubiquitination pathway involves a cascade of three enzymes (E1, E2 and E3) that 
work together to conjugate ubiquitin (Ub) to protein substrates. RING E3s are the 
biggest family of E3s and are the major focus of my research project. RING E3s are 
characterised by the presence of a RING domain that binds E2~Ub and a protein-
protein interaction domain that binds substrate(s). To facilitate Ub transfer, RING E3s 
perform several functions. Firstly, RING E3s bind E2~Ub and prime the E2~Ub 
thioester bond in a configuration that is optimal for catalysis. Secondly, RING E3s 
recruit substrate and juxtapose the E2~Ub thioester bond and ε-amino group of a 
lysine residue from the substrate to facilitate Ub transfer. Lastly, RING E3s recruit 
additional E2~Ub to catalyze polyUb chain formation. How RING E3s achieve these 
steps remains elusive. My research project focuses on understanding how RING E3s 
activate E2~Ub and catalyze Ub chain formation. 
Previously, our lab has shown that Ub bound non-covalently to the surface of 
UbcH5B opposite its active site (“backside” bound Ub or UbB) stimulates ubiquitin 
transfer in both RING-dependent and RING-independent manners, but with a more 
prominent effect in RING-dependent transfer. In this earlier work, we used a 
monomeric RING E3, RNF38, for structural analyses. To assess whether the 
mechanism of UbB-stimulation is conserved for other RING E3s, I report the structure 
of a dimeric RING E3, cIAP1 (also known as BIRC2), bound to UbcH5B–Ub and 
UbB. This complex structure is the first structure of a dimeric RING E3 bound to E2–
Ub and UbB. It is also the first structure of the cIAP1 RING domain bound to E2–Ub. 
Using structural and biochemical analysis, I show residues within the RING-
UbcH5B–Ub and UbB-UbcH5B interfaces that are important in Ub transfer. I have 
also shown that the mechanism of UbB-stimulation is conserved throughout the 
UbcH5 family (UbcH5A, UbcH5B, UbcH5C and UbcH5D) of E2’s. 
Previous studies suggest that UbcH6 lacks a UbB-binding ability despite sharing 
sequence and structural homology with the UbcH5 family. To investigate this, I 
performed NMR experiments that showed very weak binding between UbcH6 and 
Ub. To investigate further I performed autoubiquitination and lysine discharge assays 
using wild type UbcH6 (WT) and UbcH6 with Ser68 mutated to Arg to abrogate 
backside binding and found that Ub transfer was slower with UbcH6 S68R. Together 
	 3	
my results show that UbcH6 binds Ub non-covalently via its backside, but the binding 
is weak compared to the UbcH5 family of E2s. 
Finally in chapter 5, I describe my attempts to elucidate how RING E3s promote Ub 
transfer from E2~Ub onto a lysine residue of substrate. I developed a model system 
containing an E3 bound to E2~Ub and a monoubiquitinated substrate mimetic. 
Initially, I used Cbl and UbcH5B for my model since many Cbl structures have been 
determined and Cbl’s substrates are also well characterised. In the beginning, 
generating monoubiquitinated substrate mimetics was challenging, but later I 
standardised a method and showed that my substrate mimetics were functional in 
vitro. I then set up crystallisation experiments with various combinations of E3-E2–
Ub and substrate mimetics, but unfortunately all my crystals diffracted poorly. After 
many attempts to improve the diffraction quality of my crystals, I did not manage to 
get data of sufficient resolution to determine a complex structure. 
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1 Introduction 
1.1 Ubiquitin 
Ubiquitin (Ub) is a small 76-residue polypeptide found ubiquitously in all eukaryotes.  
It is attached to amino groups on target proteins and alters the function of these target 
proteins. One of the best-characterised functions of Ub-targeting is Ub-mediated 
proteolysis in which proteins tagged with Ub are directed to the 26S proteasome for 
degradation. There are seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, 
Lys48 and Lys63) present on Ub’s surface. Ub can be conjugated to its targets as a 
single moiety at one or multiple amino sites or as a polyUb chain that is linked via 
one of the seven lysine residues in Ub or via Ub’s N-terminal methionine. Different 
types of Ub modification lead to distinct biological consequences [1]. For example 
lysine 48-linked polyUb chains target protein substrates to the 26S proteasome [2] for 
degradation, whereas lysine 63-linked polyUb chains are involved in protein 
trafficking and lysosomal degradation [3]. Lys48 and Lys63-linked polyUb chains are 
the most abundant linkages found in cells and hence their function is better 
characterised. Other chains are not well-characterised, but recent studies have 
deciphered some of their roles. For example, Lys6-linked polyUb chains have shown 
an increase in abundance in mitochondrial outer membrane proteins upon organelle 
polarisation [4, 5]. The exact cellular function of Lys6 chain linkages is not well 
understood. Previous studies showed that inhibition of the proteasome does not 
increase the abundance of Lys6-linked polyUbiquitinated proteins, suggesting a non-
degradative role for this chain linkage [6, 7]. Lys6- along with Lys27-linked polyUb 
chains have been characterised as mitochondrial damage markers. Lys11-linked 
chains have shown to play an important role in proteosomal degradation and in cell 
cycle regulation. They have been identified as the specific chain linkage types utilised 
by anaphase promoting complex (APC) during mitosis [5, 8]. Lys27-along with 
Lys33-linked polyUb chains help in regulating innate immunity [9-12]. Lys29-linked 
polyUb chains are abundantly present during inhibition of the 26S proteosome, 
suggesting Lys29-linked chains function as a potential proteosomal degradation 
marker[6, 8].  Lys33-linked chains are involved in many biological processes. They 
play an important role in regulating the enzymatic activity of AMPK-related kinases 
along with Lys29-linked polyUb chains [13].  
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1.2 Ubiquitin conjugation system 
Post-translational modification of proteins by ubiquitin (Ub) is a key regulatory 
mechanism involved in a myriad of cellular processes including apoptosis, cell cycle 
and division, DNA transcription and repair, immune response and inflammation. The 
ubiquitination pathway involves a cascade of enzymes that work together to conjugate 
ubiquitin (Ub) to protein substrates. First, Ub is activated by ubiquitin-activating 
enzyme (E1) resulting in the formation of a thioester intermediate between the C-
terminus of Ub and the catalytic cysteine of E1. E1 then recruits a ubiquitin-activating 
enzyme (E2) and transfers Ub via its C-terminus to the E2’s catalytic cysteine, 
resulting in the formation of an E2~Ub thioester intermediate (~ indicates a thioester 
bond). Finally, a ubiquitin-ligase (E3) binds E2~Ub and substrate and mediates 
transfer of the C-terminus of Ub from E2 to the α-amino group of the N-terminal 
methionine or an ε-amino group of a lysine side chain on substrate, resulting in the 
formation of an isopeptide bond (Figure 1-1).  
 
Figure1-1: The ubiquitin pathway. E1 activates Ub in an ATP-dependent manner 
and forms a thioester intermediate via its catalytic cysteine to Ub. Ub is then 
transferred to E2 and finally to E3. In the last step E3 recruits both E2 and substrate 
and transfers Ub from E2 onto a substrate amino group. Figure modified from Julie 
Maupin-Furlow (2011). 
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After the discovery of Ub in the early 1970s, other ubiquitin-like molecules were 
identified and classified into a family of proteins called the ubiquitin-like proteins 
(Ubls) [14]. The best-characterised Ubls are SUMO and NEDD8. SUMO plays 
important roles in substrate localisation and protein interactions [15], whereas 
NEDD8 plays important roles in activation of Cullin-RING ligases and helps in 
regulating p53 and destabilising SCF complexes [16, 17]. Ubls have their own 
dedicated E1-E2-E3 conjugation systems and often compete with Ub for the same 
lysine sites on some substrates. For example, Ub, SUMO-1 and NEDD8 modify 
certain lysines on p53. [18] 
In the human genome, there are 2 E1s, ~30 E2s and more than 600 E3s. E3s play a 
pivotal role in determining substrate specificity and specifying the type of Ub chain 
that is attached to the substrate (Figure 1-2). There are four major groups of E3s that 
have been characterised based on their Ub transfer mechanism: HECT, RING, U-box 
and RING-between-RING (RBR). These E3s are discussed in detail in Section 1.6. 
 
 
Figure 1-2: E1-E2-E3 system and its complexity. There are two E1s, which activate 
dozens of E2s. These E2s then activate hundreds of E3s, which in turn target 
thousands of substrates. Figure modified from Nalepa et al. (2006). 
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1.3 Significance of ubiquitination 
Given the complexity of the Ub chain types that are involved in various signaling 
pathways, it is not surprising that defects in the Ub conjugation system are frequently 
associated with various diseases including cancers. Moreover, components of the Ub 
conjugation system are frequently elevated in cancer cells. The success of the 
proteasome inhibitor Velcade in treating patients with multiple myeloma has 
prompted the investigation of other therapeutic opportunities in the Ub-proteasome 
system. Based on this success, there is also great interest in targeting E1s, E2s, E3s 
and deubiquitinating enzymes (enzymes that remove Ub from the substrate, hereby 
referred to as DUBs). It is clear that a better understanding of the molecular 
mechanisms of these enzymes will assist in future therapeutic development. 
 
1.4 E1s  
E1s have a central role in the ubiquitination pathway. They initiate the ubiquitin 
conjugation cascade by activating the C-terminus of Ub. There are only two E1 genes 
present in eukaryotes, Uba1 and Uba6. Uba1 and Uba6 are monomers of about 120 
kDa. Uba1 consists of four domains: an adenylation domain, a catalytic cysteine 
domain containing the catalytic cysteine, a four- helix bundle present between the 
adenylation domain and the catalytic cysteine domain, and a C-terminal Ub-fold 
domain (Figure 1-3) [19-22]. The adenylation domain of Uba1 binds Mg2+-ATP to 
activate Ub’s C-terminal tail. Cys from the catalytic cysteine domain binds to the C-
terminal tail of Ub, resulting in the formation of a thioester bond between the two [23, 
24]. Uba1 subsequently also activates another molecule of Ub, thereby binding two 
Ub molecules simultaneously: one is bound covalently via the catalytic Cys and 
another is bound non-covalently to the adenylation active site. Ub from E1’s active 
site Cys is then transferred to an active site Cys on an E2 [24-26]. Crystal structures 
of Uba1 and Uba1 complexes (Figure 1-3A and B) show that the E2 Ubc4 binds to a 
site proximal to the catalytic Cys of the E1 whereas the body of Ub binds to 
adenylation domain, suggesting that Uba1 undergoes major conformational changes 
to catalyse the reaction [27]. 
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Figure 1-3: Crystal structures of Uba1 with Ub and with Ubc4 (A) Cartoon 
representation of the crystal structure of the Uba1-Ub complex. Uba1 is coloured 
magenta and Ub is coloured yellow. ATP and Mg2+ are respectively shown as green 
and blue spheres. Uba1’s catalytic cysteine is shown as a cyan coloured sphere (PDB 
ID: 4II3). (B) Cartoon representation of the crystal structure of the Uba1-Ubc4-Ub 
complex. Ubc4 is coloured in light blue. The catalytic cysteines of Ubc4 and Uba1 are 
shown as cyan coloured spheres (PDB ID: 4II2). 
 
1.5 E2s 
The human genome encodes ~40 E2s that are involved in the transfer of Ub or Ubls 
(e.g. SUMO, NEDD8, etc.). For RING E3s, the mechanism of Ub transfer from an E2 
to a target protein has not been completely elucidated. To date, evidence suggests that 
the ε-amino group from a substrate lysine attacks the carbonyl of the E2~Ub thioester 
to form a tetrahedral intermediate [28]. There is a highly conserved His-Pro-Asn 
(HPN) triad near the active site of all known E2s (Figure 1-4). His and Pro from this 
triad support the structure near the active site whereas Asp helps in stabilising the 
oxyanion intermediate that occurs during isopeptide formation [29]. E2s are 
characterised by the presence of a conserved catalytic ubiquitin-conjugating (UBC) 
domain. This domain is comprised of five α-helices and four anti-parallel β-strands 
[30] and contains the catalytic cysteine residue that receives Ub from the E1 to form a 
thioester bond. E2s serve as the “middle man” in the ubiquitination cascade. They 
interact with E1 and E3 during the transfer of ubiquitin to substrate. The E2 residues 
that interact with E1 and E3 overlap, suggesting that E2s cannot bind both 
simultaneously [31, 32]. Some E2s have additional N-terminal or C-terminal 
extensions. Evolutionarily, the E2 family is divided based into four classes depending 
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on these additional N- or C-terminal extensions. Class I E2s are only comprised of a 
UBC domain; Class II E2s have a UBC domain with a C-terminal extension; Class III 
E2s have a UBC domain with an N-terminal extension and Class IV E2s have a UBC 
domain with C-terminal and N-terminal extensions.  These extensions are responsible 
for the varied sizes and functions of E2s. For example, the N-terminal extension of 
UbcH10, a class III E2, plays an important role in regulation of substrate 
ubiquitination and the C-terminal extension of CDC34, a class II E2, is responsible 
for cell cycle progression, ubiquitination and localisation of E2s in cells [31, 33]. 
 
 
Figure 1-4: Overview of UBC domain E2. Cartoon representation of UbcH5B (PDB 
Id: 2FUH), a class I E2. The catalytic cysteine residue is shown as a sphere and 
coloured magenta. HPN motif residues are shown as sticks with C atoms coloured 
green, N atoms blue and O atoms red. The N-terminus and C-terminus are indicated 
by arrows. E1, E3 and backside binding sites are labelled. 
 
1.5.1 UbcH5 family 
The UbcH5 family of E2s has four homologues in humans: UbcH5A, UbcH5B, 
UbcH5C  and UbcH5D . This family of E2s is homologous to Ubc4p and Ubc5p in 
yeast [34, 35]. Members of the UbcH5 family interact with a wide range of E3s from 
both the RING and HECT families of E3s. UbcH5A, UbcH5B and UbcH5C are well-
characterised whereas not much is known about UbcH5D. The sequences of all four 
proteins in the family are highly conserved (Figure 1-5) and the structures of 
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UbcH5A, UbcH5B and UbcH5C are very similar; there are no available structures of 
UbcH5D.  
 
 
 
Figure 1-5: Sequence alignment and structures of  the UbcH5 family. (A) 
Sequence alignment of UbcH5A, UbcH5B, UbcH5C and UbcH5D using megAlign. 
Identical residues highlighted in yellow. (B) Crystal structures of UbcH5A (green) 
(PDB ID: 2C4P), UbcH5B (light blue) (PDB ID: 2CLW) and UbcH5C (magenta) 
(PDB ID: 2FUH) [36]. The catalytic cysteines are shown as orange spheres and the N-
terminal and C-terminal ends are marked. 
 
UbcH5 family proteins are highly promiscuous in their lysine selection during Ub 
transfer. They do not discriminate, and will transfer Ub to any lysine residue near the 
catalytic cysteine. For this reason, they are widely used for in vitro studies [37].  
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1.5.2  Non-covalent Ub binding to the UbcH5 family of E2s 
Brzovic et al., in 2006 first reported non-covalent binding of Ub to a surface on 
UbcH5C opposite the active site [36]. They observed binding between the Ile44 
surface of Ub and the β1-3 surface of UbcH5C (Figure1-6A). They showed that 
binding of non-covalent Ub to the backside of UbcH5C increases processivity of 
BRCA-1 directed polyUb chain formation. Mutation of Ser22 to Arg on the β-sheet of 
UbcH5C eliminated non-covalent binding of Ub. In two other studies it was 
postulated that self-assembled UbcH5B~Ub polymers bridge the gap between E2’s 
active site and substrate lysine residues [38, 39]. All the above-mentioned studies 
showed that the β1-3 surface of UbcH5 centring on Ser22 interacts with the 
hydrophobic patch of Ub surrounding Ile44. Disruption of this interaction abrogated 
RING E3 catalysed polyUb chain formation, but its mechanism was not well 
understood. In 2015, our lab determined the structure of RNF38 RING-UbcH5B–Ub 
bound to UbB (PDB ID: 4V3L) (Figure (1-6B). Together these studies showed that 
non-covalent binding of Ub to the backside of UbcH5 family members UbcH5B and 
UbcH5C is conserved. Biochemical and structural data showed that UbB enhances 
RING-dependent and RING-independent UbcH5B~Ub transfer, with RING-
dependent effects being more prominent. How this binding enhances RING-mediated 
E2~Ub transfer is discussed later in section 1.6.4.2 
 
 
Figure 1-6: Structures of UbcH5C-UbB and UbcH5B-UbB. (A) UbcH5C-UbB 
(PDB ID: 2FUH) [36]. (B) UbcH5B-UbB from RNF38-UbcH5B–Ub-UbB (PDB ID: 
4v3L) [40]. UbB is coloured in wheat and UbcH5B and UbcH5C in light blue. 
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1.5.3 Non-covalent backside binding to UbE2E family 
The human UbE2E family of proteins has three members: UbE2E1, UbE2E2 and 
UbE2E3. All members of the UbE2E families have a conserved UBC domain and 
disordered N-terminal extensions of varied lengths [33, 41, 42]. These disordered 
extensions limit chain elongation and promote monoubiquitination whereas the core 
domain builds polyubiquitin chains [43]. To characterise the function of N-terminal 
residues in UbE2E proteins, autoubiquitination of cIAP2 and RNF4 with WT and 
K0Ub (Ub in which all seven lysines are mutated to Arg) were performed. Results 
from these experiments showed that the activity of the core domain of UbcH6 was 
restricted with K0Ub, whereas full length showed similar activity with WT and 
K0Ub. Residues 10-20 of the N-terminus were shown to be essential in limiting 
polyubiquitin chain formation.  
 
                       
Figure 1-7: Structural comparison of UbcH5c-UbB and core domain of UbcH6 
(43-C). Structure of UbcH6 in green (PDB ID: 3BZH) overlaid with structure of 
UbcH5C-UbB with UbcH5C in light blue and UbB in wheat (PDB ID: 2FUH). Ser68 
of UbcH6 (shown as sticks in red) is equivalent to Ser22 of UbcH5C. 
 
Although the structures of the UbcH6 and UbcH5 families are similar and both appear 
to have the capacity to bind Ub via the backside of the E2 (Figure 1-7), in 2013 
Schumacher and colleagues [43] showed that backside binding of Ub involving 
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residue Ser68 (equivalent of Ser22 in UbcH5 family) on the β-sheet surface of UbcH6 
does not influence polyubiquitin chain formation. Their results suggest that although 
the UbcH6 family of E2s is structurally similar to the UbcH5 family, the backside β-
sheet surface might function differently than the UbcH5 family. 
1.6 E3s 
E3s, also known as ubiquitin ligases, are a large family of enzymes responsible for 
specifically targeting substrates for ubiquitination. There are four major groups of E3s 
that are characterised based on their Ub transfer mechanism: HECT, RING, U-box 
and RING-between-RING (RBR). Different E3s have different roles. Some are 
responsible for monoubiquitination of substrate whereas others regulate and catalyse 
substrate polyubiquitination [44].  All E3s function by either forming a covalent 
catalytic intermediate with ubiquitin during ubiquitin transfer (Figure 1-8C), or they 
transfer ubiquitin directly from E2~Ub to substrate (Figure 1-8A and B). The former 
mechanism is observed in HECT and RBR E3 ligases whereas the latter mechanism is 
a signature of RING and U-box E3 ligases [45]. RING domain of RING E3 ligases 
are characterised by the presence of two loops arranged in a cross brace configuration 
that are stabilised by Zn2+ which helps in binding E2s (Figure 1-8A,B); however, U-
box E3 ligases lack Zn2+ ions and are stabilised via network of hydrogen bonds. Based 
on these similarities, U-box E3s are often grouped into the RING family of E3s 
(Figure 1-8) [45]. The RING-between-RING (RBR) class of E3s behave similarly to 
the HECT E3s, except Ub is transferred from active site of RING2 domain before 
transferring onto the substrate (Figure 1-8D).  
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Figure 1-8: E3 Ubiquitin ligase families. (A) Zn2+-binding arrangement in RING E3 
ligases. (B) RING-mediated Ub transfer mechanism. (C) HECT-mediated Ub transfer 
mechanism. (D) RBR-mediated Ub transfer mechanism. Figure modified from 
Fransesca Ester Morreale and Helen Walden (2016) 
 
1.6.1 Characteristics of HECT E3 ligases 
The first family of E3s described were the HECT E3s in 1995 [46, 47]. There are 
about 28 HECT E3s in humans [48, 49]. The HECT domain is bilobal; the N-terminal 
lobe binds substrate and mediates substrate targeting whereas the C-terminal lobe 
(~350 amino acid) comprises the HECT domain, which contains the conserved 
catalytic cysteine (Figure 1-9A). Structural studies show that a hinge connecting the 
two lobes plays a critical role in juxtaposing the catalytic cysteines of E2 and E3 for 
ubiquitin transfer (Figure 1-9B) [50, 51]. HECT E3s are divided into three main 
classes depending on the presence of conserved domains or sequence motifs within 
the N-terminal region: (i) E3s containing WW domains are classified as 
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Nedd4/Nedd4-like; (ii) HERCS, which have N-terminal Rcc-1 like domain (RLD) 
and (iii) and other HECT E3s, which contain various other domains within their N-
terminal regions (Figure 1-9C) [46, 52]      
 
 
 
Figure 1-9: Domain architecture and characterisation of HECT E3 ligases. (A) 
HECT domains are bilobal. The N-lobe recruits E2~Ub and the C-lobe contains the 
catalytic cysteine that receives Ub from E2~Ub. A flexible linker between the N- and 
C-lobes is required to juxtapose Ub and its target. (B) Crystal structure of NEDD4L-
UbcH5B-Ub (PDB ID: 3JWO). UbcH5B is coloured in magenta, NEDD4L in blue 
and Ub is in orange. Catalytic Cys of UbcH5B and NEDD4L are shown in cyan 
sphere. (C) Class I HECT E3 ligases containing WW domains. Class II HECT E3 
ligases contain RLDS and HECT domains and class III contain various domains. 
Figure modified from Fransesca Ester Morreale and Helen Walden (2016). 
 
1.6.2 Characteristics of RING E3 ligases 
There are more than 600 RING E3s found in mammalian cells, making it the largest 
family of E3 ligases. RING E3s are recognised by the presence of a RING domain. 
RING domains comprise ~75-100 amino acids and are characterised by the presence 
of two Zn2+-coordinating loops (Figure 1-10A). These Zn2+ ions are required for 
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structural stability.  RING domains recruit E2~Ub and promoting Ub transfer, 
Structural studies have shown that any mutation in these Zn2+-coordinating loops 
leads to functional aberrations [48, 53]. RING E3s can be divided into three major 
classes: monomeric, dimeric or multi-subunit complexes (Figure 1-10). 
 
 
 
Figure 1-10: Domain architecture of RING E3s. (A) Schematic of a monomeric 
RING E3 (B) Crystal structure of the monomeric RING E3 c-Cbl (PDB ID: 2YIN), 
comprising a RING domain to recruit E2~Ub and a substrate-binding domain. The 
substrate binding domain is coloured green and the RING domain is orange. Zn2+ ions 
are shown as grey spheres. (C) Schematic of a dimeric RING E3. (D) Crystal 
structure of the homodimeric RING domain of CIAP2 (PDB ID: 3EB6) with Zn2+ 
ions shown as in B. (E) Crystal structure of the heterodimeric RING domain of 
MDM2-MDMX (PDB ID: 2VJE) MDM2 is coloured in green and MDMX in cyan 
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and Zn2+ ions are shown as in B. (F) Schematic of a multi-subunit RING E3. (G) 
Crystal structure of full length CRL2 (PDB ID: 5N4W). The Cul-2 subunit is 
coloured in green, the substrate-binding receptor in magenta, and Elongin B and 
Elongin C are in sand and blue, respectively. The RING subunit (Rbx1) is coloured in 
orange and Zn2+ ions are shown as in B. 
 
Monomeric RING E3s like the Cbl family and RNF38 have a RING domain for 
recruiting E2~Ub and a substrate-binding domain or domain(s) encoded on a single 
polypeptide chain (Figure 1-11A). In RING E3 dimers, the RING domain and 
surrounding regions contribute to the dimer interface. Some RING E3s form 
homodimers as in cIAP (cellular inhibitor of apoptosis) (Figure1-11B) and others 
form heterodimers as in MDM2 (murine double minute 2) with MDMX (known as 
MDM4) (Figure 1-11C). In some heterodimers like MDM2/MDMX, one of the RING 
domains lacks ligase activity and instead functions to stabilise E2~Ub binding by the 
second RING domain [50]. Multi-subunit RING E3 ligases like the Cullin RING E3 
ligase (CRL) superfamily make up the largest number of RING E3s (Figure 1-11D). 
Each subunit of the CRL is encoded on a single polypeptide chain. CRLs consist of a 
Cullin subunit (Cul-1, 2, 3, 4a, 4b, 5 or 7), a RING subunit such as RBX1, RBX2, or 
Hrt1 and a substrate binding receptor subunit from the F-box, SOCS or BTB family. 
The Cullin domain acts as scaffold in which the RING and substrate receptor subunits 
are mounted [48]. The most studied CRL superfamily is the Skp1-Cul1-F-box protein 
(SCF) family. Another example of a multi-subunit RING superfamily is the anaphase 
promoting complex/cyclosome (APC/C) (Figure 1-11D). It consists of 19 subunits, 
including a RING subunit (APC11) and a Cullin-like subunit (APC2) [54]. 
 
1.6.3 Characteristics of Ring between Ring (RBR) ligases 
The RING between RING (RBR) family of proteins is characterised by the presence 
of two RING domains. The N-terminal RING domain binds E2 and the C-terminal 
RING domain contains the catalytic Cys used to form the E3~Ub thioester. The N-
terminal RING is followed by a cluster of cysteine and histidine residues that form the 
in between RING (IBR) region. In the best characterised members of the RBR E3s, 
namely Parkin and HOIP, the C-terminal IBR region contains a third RING domain 
that only binds one Zn2+-ion and forms a hydrophobic core [55, 56].  In Parkin, this 
IBR RING domain is essential for function but this is not a feature common to all 
RBR ligases [57]. The catalytic cysteine of RBR E3s is frequently buried,, suggesting 
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they are autoinhibited [58-61]. Recent structural studies on Parkin and HOIP reveal 
how RBR E3s are regulated (Figure:1-11A) and how they recruit E2~Ub (Figure:1-
11B). 
 
 
Figure 1-11: Structures of Parkin and HOIP/E2–Ub of RBR ligases (A) Crystal 
structure of a fragment of Parkin comprising the RING0 and RBR domains (PDB Id: 
4I1F). (B) Crystal structure of a HOIP-UbcH5B–Ub complex (PDB ID:5edv). Each 
domain is labeled in the same colour in which it is shown. 
 
 
Structural basis of RING E3 activity 
RING E3 ligases serve as the biggest group of E3 ligases with ~600 RING E3s found 
in humans. Presence of RING E3 stimulates the Ub transfer from E2’s active site onto 
the substrate’s lysine site. The method of their stimulation was not very well 
understood until the first structure of c-Cbl-UbcH7-ZAP70 was solved [28, 40, 62, 
63]. In the following sections, I have discussed about the RING E3-E2 interacting 
surface and how it activates E2~Ub transfer. 
 
1.6.4 RING E3-E2 interface 
The first step in E2~Ub activation by RING E3 ligases involves binding of the RING 
domain from the E3 to E2~Ub. The E3 selects E2~Ub and the target protein and the 
E3-E2~Ub pair determines how the substrate is modified [30]. A plethora of structural 
and molecular information on E3-E2 binding shows that the binding surfaces present 
on E3s and E2s are highly conserved, yet specific E2-E3 pairs exists in nature with 
some pairs being unique [33, 64, 65]. In all available complex structures of E3 bound 
to E2, loops 1 and 2 and the N-terminal α-helix of the E2 interact with the 
hydrophobic surface co-ordinated by Zn2+-ions on the E3 RING domain [62, 66-69]. 
The first structure to show RING E3-E2 binding was that of c-Cbl bound to UbcH7 
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(Figure 12A). As shown in the figure below, Phe63 in loop 1 and Pro97 and Ala98 in 
loop 2 of UbcH7 pack closely within the groove between the Zn2+-ions of the RING 
domain. Arg5 and Arg15 from the N-terminal α-helix of UbcH7 also interact with the 
linker region of c-Cbl [62] (Figure 12B). Although UbcH7 has been used in early 
structural studies with RING E3s, later studies have shown it to be reactive towards 
cysteine and not lysine. Therefore, UbcH7 can bind many RING E3s but is only 
reactive with HECT E3 ligases [63]. 
 
 
Figure 1-12: Illustration of RING E3-E2 binding. (A) Structure of c-Cbl bound to 
UbcH7 (PDB ID: 1FBV) [62] with the RING domain coloured in orange and the 
substrate binding domain in green; the Zn2+-ions are depicted as grey spheres. UbcH7 
is coloured light blue. The catalytic Cys of the E2 is shown as a red sphere, and loops 
1 and 2 of are coloured in blue and magenta, respectively.  (B) Close-up of the 
interaction between c-Cbl’s RING domain and UbcH7. UbcH7’s Phe63, Pro97 from 
loop 1, and Ala98 from loop 2 bind within the groove formed by c-Cbl’s Zn2+-ion 
coordination sites. In addition, Arg5 and Arg15 from UbcH7’s α-helix interact with 
the linker of c-Cbl. These residues are shown as sticks with C atoms coloured as in A, 
N atoms blue and O atoms red.  
 
A single E2 can bind multiple E3s, suggesting that different residues from E2s can be 
responsible for binding different E3s [30, 70, 71]. The binding affinity between E3 
and E2 is weak ranging from 1.2 µM to 2 mM range [30, 71]. This low affinity 
binding is essential since the binding sites for E1 and E3 overlap on E2s. In order to 
be charged again by E1, E2s first needs to disengage from E3s. 
 
 
	 32	
1.6.5 RING E3 activates E2~Ub 
RING E3s transfer Ub directly onto a substrate lysine without forming an E3~Ub 
intermediate. Early RING E3-E2 structures showed that the binding interface is not 
near E2’s active site [62, 70, 71]. In 2005, Ozkan et al. identified Ile37 as one of 
several mutants outside of the E2 active site that causes defects in E3-mediated Ub 
transfer [28]. Based on these studies, RING E3s were reputed to promote Ub transfer 
by inducing allosteric changes in E2~Ub. Similar allosteric effects were also shown 
by E4B binding to UbcH5C and Ubc4. [72]. To gain structural and biochemical 
insights into how RING E3s stabilise E2~Ub to promote Ub transfer, it was necessary 
to capture RING E3 bound to E2~Ub. However, in the presence of a RING E3, 
E2~Ub is unstable and Ub is readily transferred to accessible lysines. Therefore to 
capture a structure of a RING E3 bound to E2~Ub, Plechanovova et al., (2011) and 
Dou et al. (2012) respectively crystallised complexes of E3s bound to UbcH5A–Ub 
and UbcH5B–Ub. In these studies, the E2~Ub thioester bond was replaced by 
mutating E2’s active site Cys to Lys in RNF4-UbcH5A–Ub structure and Cys to Ser 
in Birc7-UbcH5B–Ub structure forming a stable isopeptide and oxyester bond 
respectively. [66, 67]. Since 2012, many more structures of RING E3 bound to 
E2~Ub have been published [40, 66, 68, 73, 74].  These E3-E2–Ub and E3-E2 
structures showed that there are no major conformational changes in the E2 upon 
binding E3, regardless of whether it is E2 alone or E2~Ub. However, NMR studies 
revealed striking differences in the dynamics between ‘open’ and ‘closed’ 
conformations of E2~Ub in the presence of a RING E3 [66-68].  As shown in Figure 
1-13A, in the absence of a RING E3, E2~Ub is dynamic and primarily adopts open 
conformations in which there are no or minimal interactions between E2 and the 
conjugated Ub. For the UbcH5 family of E2s, the addition of a RING E3 induces 
E2~Ub to adopt closed conformations. Structural studies revealed that the RING E3 
directly contacts the C-terminal tail of E2~Ub to stabilise Ub in a conformation 
primed for transfer [39, 66, 68, 75]. 
1.6.5.1 Direct interactions between RING E3 and E2~Ub 
The above-mentioned structural studies revealed the presence of a linchpin Arg in 
RING E3s. This Arg forms hydrogen bonds with Ub and E2, thereby stabilising 
E2~Ub in the closed conformation [48, 66, 68, 76]. The linching Arg from the RING 
domain interacts directly with the main chain of Arg72 of Ub and Gln92 of UbcH5B 
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(Figure 1-13E). For dimeric RING E3s like cIAP1, cIAP2, RNF4, and BIRC7, the C-
terminal tail of each subunit contributes to the dimer interface. The C-terminal tail of 
one RING subunit interacts with other RING subunit and binds the Gly35-surface of 
Ub to stabilise E2~Ub in a closed conformation (Figure 1-13D) [66, 67, 77]. Arg606 
plays a crucial role by pinning UbD and UbcH5B together. It stabilizes UbD by 
forming hydrogen bonds with Arg72 and Glu40 of UbD. Direct interactions between 
Arg606 of cIAP1R and Arg72 of UbD constrain the C-terminal tail of ubiquitin in a 
conformation in which the thioester is more reactive. Apart from cIAP1R’s Phe616 
and Arg606, Ile36 of UbD interacts with cIAP1R’s C-terminus and RING domain via 
hydrophobic and hydrophilic interactions (Figure 1-13D). These interactions provide 
additional stability to RING-UbD interactions. These interactions consist of Arg614 at 
the C-terminus of cIAP1R forming a hydrogen bond with Asp32 of UbD, and His588, 
Ileu604 and Cys592 from cIAP1R’s RING domain interacting with Leu8, Ileu36 and 
Pro37 of UbD (Figure 1-13D). Apart from the C-terminal tail of RING E3s, E2s also 
play an important role in stabilising Ub. Ubiquitin’s Ileu44 patch interacts with the 
α3-helix of UbcH5B (Figure 1-13E). The interactions between UbcH5B and Ub are 
stabilized by hydrophobic interactions between Ser108 of UbcH5B and His68 and 
Val70 of Ub. These interactions were also previously observed in the complex 
structure of BIRC7 bound to UbcH5B~Ub (Dou et al. 2012). Additional interactions 
are also observed between Lys48, Gln49,and Arg42 of Ub and UbcH5B’s Asp112, 
Leu104,and Lys101 (Figure 1-13E). The C-terminal tail of Ub is extended and lies 
along the interface between UbcH5B’s helices (Figure 1-13C). As shown in the 
figure, hydrophobic interactions are formed between UbcH5B’s Ileu88 and Ub’s 
Leu73. Other interactions shown in figure are between backbone nitrogen of UbcH5B 
Asp87 and the backbone oxygen of Ub’s Arg74 (Figure 1-13C). Most E2s contain a 
His-Pro-Asn (HPN) motif near the active site that is important for catalysis. Based on 
numbering from the UbcH5 family of E2s, residues 114-117 comprise a loop near the 
active site and Asn77 from the HPN motif helps stabilize this loop via interactions 
with the main chain of Asn114 (Figure 1-13C) [48, 67, 78].   
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Figure 1-13: Mechanism for stabilizing E2~Ub by RING E3s. (A) E2~Ub is 
dynamic, shifting between open and closed conformations. Figure on left shows, 
E2~Ub in open conformations. Figure on right shows stabilized E2~Ub in the closed 
conformation upon adding E3. (B) cIAP1 bound to UbcH5B–Ub.Zn2+ ions are shown 
as grey spheres, UbcH5B is coloured light blue, Ub in yellow, cIAP-1 RING in 
orange. (C) Close-up view of the active site of UbcH5B–Ub. Asn77 forms hydrogen 
bonds with the main chains of Asn114. Asp117 reduces the pKa of substrate lysine 
[67]. (D) Close-up of view of cIAP1homodimerisation interface. The C-terminal tail 
of cIAP1 from one protomer packs against Ub. (E) Close-up view of linchpin Arg 
interaction network. cIAP1 Arg606 makes contacts with Gln92 of UbcH5B and 
Glu40 and Arg72 of Ub. This interaction helps to stabilize Ub in the closed 
conformation. 
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1.6.5.2 Indirect role of RING E3s for optimal Ub transfer 
Several factors contribute to priming E2~Ub for catalysis in addition to direct RING-
E2~Ub interactions. 
Phosphorylation: Cbl proteins (Cbl-b, c-Cbl and Cbl-c) are a family of RING E3 
ligases responsible for targeting receptor tyrosine kinases (RTKs) for degradation by 
ubiquitination, endocytosis and subsequent lysosomal degradation [79-82]. Using 
mutational studies, Levkowitz et al., (1999) found that Tyr371 is critical for activating 
c-Cbl. This was further supported by studies carried out by Kassenbrock et al. (2004) 
in which they also showed the importance of Tyr371 phosphorylation. In contrast, 
structural studies by Zheng et al.,(2000) showed that c-Cbl bound E2 without 
phosphorylation of Tyr371 and that Tyr371 was buried in a pocket that cannot 
accommodate a phosphate moiety (Figure 1-14A) [62, 83]. More recent studies have 
shown that UbcH7 does not work with RING E3s. In 2012, Dou et al., determined the 
crystal structure of Tyr371-phosphorylated c-Cbl (pc-Cbl) bound to UbcH5B and 
ZAP70 peptide and showed that Tyr371 phosphorylation induces conformational 
changes in the linker helix region (LHR) of c-Cbl such that it no longer is in an 
autoinhibited state (Figure 1-14B). The phosphorylation of a strictly conserved 
tyrosine in the LHR within the N terminal region of Cbl proteins is important for its 
activation [84, 85]. The structure of pCbl-b bound to UbcH5B–Ub with ZAP70 
peptide (Figure 1-14C) shows that the strictly conserved phosphorylated tyrosine 
(pTyr363) in the LHR of the N-terminal fragment of Cbl-b forms a hydrogen bond 
with Thr9 of Ub, thereby stabilising E2~Ub (Figure 1-14D). 
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Figure 1-14: Phosphorylation of a conserved tyrosine residue activates Cbl. (A) 
Structure of c-Cbl bound to UbcH7 and ZAP70 peptide. The substrate binding domain 
of c-Cbl is coloured in green, the LHR in pink and the RING domain in orange. Zn2+-
ions are shown as grey spheres and Tyr371 is in red sticks. UbcH7 is in light blue and 
the catalytic Cys is shown in red spheres. Zap70 peptide is in cyan. (PDB ID: 1FBV) 
(B) Structure of pc-Cbl bound to UbcH5B and ZAP70 peptide. Coloured as in A 
(PDB ID: 4A4C). (C) Structure of pCbl-b bound to UbcH5B–Ub and Zap70 peptide, 
coloured as in A and with Ub in light green (PDB ID: 3ZNI)  (D) Close-up of the 
interaction between the LHR of pCbl-b and Ub, coloured as in A. Key residues from 
Ub are shown as sticks with C atoms in light green and O atoms in red. C atoms from 
pTyr363 are shown in red, P atoms in orange and O atoms in red. The dashed line 
indicates a putative hydrogen bond. 
 
Backside binding to E2s: Some RING E3s have an additional domain that binds 
to the backside of certain E2s [45, 86, 87]. For example, the RING E3 gp78 binds to 
the backside of the E2 Ube2g2; this region of gp78 is called G2BR (Figure1-15A). 
G2BR is a single α-helix that binds perpendicularly to Ube2g2. G2BR binding 
allosterically stimulates Ube2g2 in two ways: (i) G2BR locks the catalytic cysteine 
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loop of Ube2g2 and orients it into a closed conformation and (ii) it increases the 
affinity of Ube2g2 for gp78, which leads to stimulation of ubiquitination. This 
interaction has very high binding affinity (~21nm), which helps in increased 
ubiquitylation by Ube2ge and G2BR [45, 86]. Another RING E3, Cue1p, binds to the 
backside of the E2 Ubc7p via a domain called Ub7BR (Figure 1-15B). The Ubc7p-
Ub7BR interaction occurs distal to Ubc7p’s active E3-binding sites. Backside binding 
by Ub7BR does not affect the overall structure of Ubc7p but instead alters loops 
surrounding the catalytic Cys. When Ub7BR binds to the backside of Ubc7p, loops 
surrounding Ubc7p’s catalytic Cys move away from the active site, making it more 
accessible to substrate and to E1 for charging for subsequent rounds of ubiquitination. 
In addition, Ub7BR enhances E3-E2 binding affinity [88, 89].   
Another RING E3, Rad18, competes with ubiquitin for non-covalent backside binding 
to the E2 Rad6 [45, 87]. The Rad18/Rad6 backside interaction promotes substrate 
monoubiquitination rather than polyubiquitination. Rad18 binds to the backside of 
Rad6 through its C-terminal domain, called Rad6 binding domain (Rad6BD) (Figure 
1-15C). Unlike Ubc7p-Ub7BR binding, Rad18 does not enhance the rate of Rad6~Ub 
thioester formation; instead it limits the polyubiquitin chain formation by Rad6. NMR 
studies showed that binding of Rad6BD peptide to Rad6 does not induce any 
structural changes, except that Rad6BD is in a more compact conformation when 
bound to Rad6 [87]. 
Similar to Rad18, another RING E3 called AO7/RNF25 also contains a domain that 
competes with Ub for non-covalent binding to the backside of the E2 UbcH5B. AO7 
binds the backside of UbcH5B via its unique UbcH5B recognition domain called 
U5BR and a linker, which connects to its RING domain (Figure 1-15D). This acts like 
a clamp and prevents interactions between UbcH5B’s backside and Ub. The binding 
affinity between U5BR and UbcH5B is very strong, and unlike other E3s, U5BR does 
not enhance the rate of E2~Ub transfer. This might occur because its primary function 
is to prevent backside Ub binding; however if the local concentration of E2 bound to 
backside Ub is low, the U5BR-UbcH5B interaction enhances rate of E2~Ub transfer. 
Hence the role of AO7-UbcH5B binding is a paradox in that it increases or decreases 
E3 activity depending on the requirement [90]. 
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Figure 1-15: E3 binding to E2’s backside enhances E2~Ub transfer. (A) Structure 
of Ube2g2 bound to G2BR (PDB ID: 3H8K). (B) Structure of Ubc7p bound to cue1p 
(PDB ID: 4JQU) (C) Structure of Rad6 bound to Rad18 (PDB ID: 2YBF). (D) 
Structure of UbcH5B bound to AO7 (PDB ID: 5D1K). 
 
Apart from non-covalent binding of E3 domains outside of the RING domain to the 
backside of select E2s as discussed above, Ub also binds the backside of select E2s 
non-covalently to enhance E2~Ub activity. As discussed earlier in Sections 1.5.2 and 
1.5.3, Ub has been shown to bind to the backside of several E2s including the UbcH5, 
Rad6 and Ube2g2 families [36, 40, 87]. In 2006, Brzovic et al. showed for the first 
time that Ub bound non-covalently to the backside of UbcH5C. The structure revealed 
that Ub’s Ileu44 patch is involved in interacting with the backside surface of UbcH5C 
centring residue Ser22. They also showed when Ser22 is mutated to Arg, UbcH5C 
loses its ability to bind Ub. After this many other groups also demonstrated evidence 
of non-covalent binding of Ub to E2’s backside, but they could not explain the 
relevance in vivo based on its low binding affinity to E2 [36, 38, 91, 92]. In 2015, our 
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lab presented detailed biochemical studies showing that non-covalent Ub binding to 
the backside of UbcH5B in RING-dependent and RING-independent manners 
stimulates Ub transfer, with a more prominent effect in RING-dependent transfer. 
Along with these biochemical studies, we determined crystal structures of complexes 
of RNF38 bound to UbcH5B–Ub with and without backside Ub (UbB). The structures 
showed a conformational change in the α1β1 loop of UbcH5B in the presence of UbB. 
The α1β1 loop of UbcH5B is more restricted in the presence of UbB, which in turn 
facilitates E2~Ub adopting a closed conformation that is primed for Ub transfer upon 
binding to the RING domain. When E2~Ub is in the closed conformation, the C-
terminal tail of Ub is optimally aligned in E2’s active site cleft such that the E2~Ub 
thioester bond is oriented for nucleophilic attack by a substrate lysine residue [40, 66-
68]. SPR results showed that UbB enhances RING E3’s binding affinity for 
UbcH5B~Ub by 12-fold and RING E3-E2~Ub complex enhances UbB’s affinity for 
the backside of E2 by 20-fold. This explains how a weak UbB-E2 interaction (Kd ~ 
300 µM) could become relevant in cells where Ub concentrations are between 20-85 
µM [40].  
1.6.6 Substrate targeting by RING E3s 
One of the key functions of RING E3s is to bring E2~Ub and substrate lysine into 
proximity for ubiquitination. Substrate regulation via RING E3s involves two crucial 
points, substrate identification and substrate ubiquitination. Substrate identification 
occurs via direct or indirect protein-protein interactions. For example, Cbl has a 
substrate-binding domain (SBD) that recognises and binds phosphorylated EGFR and 
targets it for lysosomal degradation. It also binds an additional EGFR-interacting 
protein GRB2, which helps Cbl to recruit EGFR [48, 81, 93]. 
1.6.7 Methods to identify RING E3-substrate interactions 
E3 ligases are very complex and this makes identification of specific E3 targets 
difficult. There are several factors responsible for this complexity including the 
following: (i) Several hundred RING E3 ligases are responsible for targeting 
thousands of substrates, and within this system, there is redundancy in substrate 
identification as illustrated in Figure 1-2; (ii) In the presence of RING E3 ligases the 
transfer of Ub is very rapid, resulting in E3-substrate complexes only having a short 
lifetime [40, 48, 66-68]; (iii) For some E3 ligases the E3-substrate interaction is very 
weak, making identification of these E3 targets challenging [94]; (iv) Cellular 
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concentrations of some substrates are very low [95]. All these factors hinder current 
methods that have are available to identify substrates [95-97]. Also some RING E3 
ligases like Cbls only target their substrates following post-translational 
modifications, and pathways triggering these post-translational modifcations must be 
activated to isolate such targets. The methods developed to date are not capable of 
detecting such modifications [8, 48]. Moreover differences in mechanisms among the 
three E3 ligases classes (HECT, RING and RBR) also contributes difficulties in 
identifying substrates and validating the role of select E3s in modifying these 
substrates in cells [98]. 
In spite of all above challenges, some progress has been made in developing 
methodologies that can be used to identify specific E3-substrate interactions [98]. 
Examples include yeast two-hybrid screening (Y2H), phage display, advances in 
proteomics, and development of antibodies that identify motifs like the diGly (Gly 
Gly) motif at the C-terminus of Ub and other Ubls and specific polyUb chain linkages 
etc. [6, 7, 99-101]. Substrate ubiquitination occurs via attachment of Ub onto the side 
chain of a substrate lysine residue, thereby forming an isopeptide bond. Ub possesses 
seven lysine residues on its surface, which serve as sites for Ub attachment in the 
formation of polyUb chains. Specific linkages define the fate of the substrate; 
examples include degradation via the proteasome or lysome and, localisation to sites 
of DNA repair. Studies have shown that all types of linkages co-exist in cells [6, 7, 
102]. Post-translational modifications of RING E3s or substrates are the most 
common modifications that regulate substrate ubiquitination. For example, Cbl is 
activated by phosphorylation (Section 1.6.4.2). In Cbl, the substrate-binding site is 
located on a Src Homology 2 (SH2) domain, which recognises tyrosine-
phosphorylated proteins for substrate regulation. Similarly dimeric MDM2/MDMX 
recruits its substrate p53 via regions N-terminal of the RING domain. Multi-
component RING E3s like CRLs recruit multiple subunits including a RING domain 
to bind E2~Ub and a substrate binding receptor domain for substrate recognition. F-
box proteins are the best-characterised proteins so far (Figure1-11, Section 1.6.2). 
There is still a demand for more comprehensive studies to elucidate mechanisms of 
substrate selection and regulation by RING E3s. 
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1.7 Cbl proteins 
1.7.1 Discovery 
Cbl (Casitas B-lineage lymphoma) was first identified as v-Cbl, an oncogenic protein 
that causes pre-B lymphoma in mice [103, 104]. The cellular form, c-Cbl, is present 
ubiquitously in mammals, localised within the cytoplasm, and expressed highly in 
testis and hematopoietic cells [105]. The mammalian Cbl family consists of three 
homologues: c-Cbl, Cbl-b and Cbl-c. 
1.7.2 Domain Organisation 
The N-terminal region of Cbl is highly conserved. All three mammalian Cbl 
homologues (c-Cbl, Cbl-b and Cbl-c) consist of a tyrosine kinase binding domain 
(TKBD) that only binds tyrosine-phosphorylated polypeptides. This domain is made 
up of four helical (4H) bundles followed by a calcium binding EF hand and a variant 
SH2 domain. This region is responsible for binding substrates. The TKBD domain is 
then followed by a short LHR and a RING domain. The LHR and RING bind E2~Ub 
[62]. c-Cbl and Cbl-b contain an additional proline rich region that mediates protein-
protein interactions. Both Cbl-b and c-Cbl have a Ub associated (UBA) domain at 
their C-termini known to promote dimerisation in experimental conditions (Figure 1-
16) [106, 107]. 
 
 
 
Figure 1-16: Domain Organisation of Cbl family of proteins 
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1.7.3   Cbl activity and functions 
The Cbl family of proteins ubiquitylates and thereby facilitates degradation and 
downregulation of protein tyrosine kinases (PTKs). EGFR is the best-characterised 
target of Cbl to date [80, 81]. Auto-phosphorylated EGFR directly binds to the TKBD 
domain of c-Cbl via its phosphorylated Tyr1045 residue [108, 109]. Alternatively c-
Cbl can bind to EGFR indirectly via an adaptor protein called Grb2. Grb2 interacts 
with EGFR and c-Cbl via its SH2 and SH3 domains respectively [93]. Other SH3 
domain containing proteins like CIN85 also bind to c-Cbl via their SH3 domains. 
Binding to CIN85 indirectly helps in downregulation of EGFR. If the c-Cbl-CIN85 
interaction is impaired, it leads to overexpression of EGFR whereas if the binding is 
sustained it leads to internalisation and ubiquitylation of EGFR [104]. Cbls 
themselves are negatively regulated by Sprouty2 (Spry2). Spry2 binds to the RING 
domain and the SH2 domain after being activated by EGFR. This mechanism induces 
phosphorylation in Spry2, which in turn blocks activated receptors from binding to 
the SH2 and RING domains of Cbl. Hence Spry2 is responsible for modulating 
negative regulation of active RTKs by c-Cbl [104]. In addition to EGFR, the Cbl 
family also downregulates a variety of other PTKs like platelet derived growth factor 
(PDGF) and colony stimulating factor (CSF-1) [110, 111]. In addition, c-Cbl 
downregulates a number of non-receptor tyrosine kinases like Syk, Lck, Fyn, Hck, 
Fgr and c-Abl [112-117]. 
 
1.7.4 Cbl as a ubiquitin ligase 
The basic functional unit of Cbl required for substrate ubiquitination comprises the 
TKBD, LHR and RING finger domains. This is also the minimal unit required to 
ubiquitinate and downregulate activated PTKs in cells [81, 118-120]. The conserved 
C-terminal regions of c-Cbl and Cbl-b are involved in additional protein-protein 
interactions [105]. For example, the proline rich regions in c-Cbl and Cbl-b bind Src 
and are important for Cbl-mediated ubiquitination of Src. [121], even though Src-
binding via the TKBD is also observed [122]. In the earliest structural studies 
performed with the minimal active ligase fragment of c-Cbl, c-Cbl was bound to 
UbcH7 and ZAP70 peptide. In this complex structure, the E2 is facing away from 
substrate-binding site and there is a gap of 70 Å between the substrate-binding site 
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and E2’s active site [62]. Later a structure of phosphorylated c-Cbl bound to UbcH5B 
and ZAP70 peptide showed that this gap is bridged and reduced to 27 Å when c-Cbl’s 
LHR is phosphorylated [85]. When the conserved Tyr (Tyr371 in c-Cbl) in the LHR 
is phosphorylated, the LHR is detached from the TKBD and becomes more flexible. 
This allows the RING domain to rotate about a hinge loop connecting the TKBD and 
LHR, thereby enabling juxtaposition of E2~Ub and the substrate-binding site. 
Moreover, phosphorylated Tyr371 engages interactions with the RING domain to 
form a new E2~Ub binding platform to enhance E2~Ub binding affinity. Notably 
phosphorylated Tyr371 or Tyr363 in Cbl-b directly contacts the donor Ub to stabilise 
the closed E2~Ub conformation. There are no structures of Cbl bound to intact 
substrate that illustrate how Cbl mediates Ub transfer to substrate. I have discussed 
this topic in detail in chapter 5, where I have attempted to capture a complex of Cbl 
bound to E2~Ub and substrate mimetic. 
 
1.8 Cellular Inhibitor of Apoptosis proteins (cIAPs) 
1.8.1 Role of IAPs in signalling pathways 
cIAPs act as major regulators of cell death and survival [123] by modulating nuclear 
factor kappa B (NF-κB) signalling pathways. In unstimulated conditions NF-κB is 
restrained to the cytoplasm by its inhibitor I kappa B (IκB). Upon stimulation IκB 
undergoes phosphorylation by the IκB kinase complex (IKK) comprised of IKKα, 
IKKβ and a regulatory subunit, IKKγ [124]. Activation of NF-κB signalling occurs 
via one of two pathways: canonical (classical) or non-canonical (alternative) (Figure 
1-17). There are many signalling factors responsible for activation of NF-κB 
including tumour necrosis factor alpha (TNF-α), an inflammatory cytokine [125]. 
When TNF-α binds to the receptor, tumour necrosis factor-1 (TNF-R1), it triggers 
activation of the NF-κB signalling pathway. In the canonical pathway, cIAP-1 and 
cIAP-2 are recruited to the TNF receptors via TNFR-associated factor (TRAF2), 
TRAF2 mediates formation a complex with the cIAP substrate, receptor interacting 
protein-1 (RIP-1) [123, 126]. cIAP1 and cIAP2 promote K63-linked 
polyubiquitination of RIP-1 [127]. Ubiquitinated RIP-1 recruits TAK-1-binding 
protein (TAB) and TGFβ activated kinase-1 (TAK1), which stimulates activation of 
IKKβ. This leads to degradation of IKβ and translocates two subunits of NF-κB, p50 
and transcription factor RELA, to the nucleus [123]. In the non-canonical pathway, 
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cIAP-1 acts as a negative regulator of NF-κB signalling by promoting ubiquitylation 
and proteosomal degradation of NF-κB-inducing kinase (NIK) as part of a cIAP-
TRAF2-TRAF3 complex [128, 129]. Protein levels of NIK are very low in 
unstimulated cells because of continuous ubiquitination by cIAP-TRAF2-TRAF3 
complexes. Binding of various TNF receptors like TWEAK and CD40 to their 
partners promotes ubiquitination of TRAF2 and TRAF3 and autoubiquitination of 
cIAPs. This leads to the accumulation of NIK. This in turn leads to phosphorylation 
and activation of IKKα, which leads to phosphorylation of p100 (also called NF-κB2). 
This precursor p100 leads to partial proteosomal processing to generate 
transcriptionally active p52 [123, 129]. Hence cIAP proteins act as positive and 
negative regulators of NF-κB signalling pathways. These contrasting roles illustrate 
how necessary it is to regulate E3 ligase activity during signalling events. 
 
 
 
                              
Figure 1-17: Canonical and non-canonical pathways of NF-κB signalling. cIAPs 
act as positive regulators of canonical NF-κB signalling (left) and negative regulators 
of non-canonical NF-κB signalling pathways. Figure adapted from Simone Fulda and 
Domagoj Vucic (2012). 
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1.8.2 IAPs as ubiquitin ligase 
Miller and colleagues first described IAPs in baculoviral genomes about 25 years ago 
[130-132]. All members of the IAP family possess at least one baculovirus IAP repeat 
(BIR) domain; BIR domains are characterised by the presence of a Zn2+-binding site 
and are frequently involved in protein-protein interactions. BIR domains facilitate 
anti-apoptotic IAP features by interacting with the TRAF-N domain of TNF [128, 
133, 134]. A number of IAPs also possess a RING domain that confers RING E3 
ligase activity in the form of autoubiquitination and ubiquitination of proteins 
involved in apoptosis and signalling [123]. cIAP-1, cIAP-2 and XIAP also possess a 
UBA domain and the cIAPs also have a CARD domain (Figure 1-18) 
 
 
 
             Figure 1-18: Domain organisation of human IAP family of  proteins 
 
XIAP, cIAP-1 and cIAP-2 all possess ubiquitin ligase activity that is conferred by the 
presence of a C-terminal RING domain. cIAP-1 undergoes dimerisation through its 
RING domain to become an active ligase [135-138]. When unactivated, cIAP-1 exists 
in a monomeric autoinhibited state in which the RING domain is tucked away through 
inter-domain interactions between the BIR, CARD and UBA domains. All three of 
these IAPs inhibit apoptosis by binding caspases and ubiquitinating them, thereby 
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targeting them for degradation, or by binding caspases and maintaining them in an 
inactive state. When outer membrane permeabilisation is triggered, a mature form of second	mitochondria-derived	 activator	 of	 caspases	 (SMAC) promotes apoptosis 
by binding to BIR domains of these IAPs and preventing their interactions with 
caspases [135, 139]. A peptide Ala-Val-Pro-Ile (AVPI) of the first four residues in 
SMAC reproduces this effect. Binding of SMAC-peptide in vitro disrupts the BIR3-
RING interface in autoinhibited cIAP-1, thereby promoting dimerisation and 
activating auto- and substrate ubiquitination.  
 
1.8.3 Available structures of cIAPs 
cIAP-1 and cIAP-2 have similar domain architectures (Figure 1-18). There is no 
structure available for either full-length cIAP. For cIAP-2, there is a structure of the 
RING domain alone (PDB ID: 3EB5) and bound to UbcH5B (Figure 1-19 (A)) (PDB 
ID: 3EB6) [77] and the BIR3 domain alone (PDB ID: 2UVL) [140](Figure 1-19B). In 
the cIAP-2 structure of the RING alone and with UbcH5B, the C-terminal tail plays 
an important role in dimerisation. cIAP-2 interacts with its substrates via its BIR 
domains. To date, there are no structures of either cIAP bound to E2~Ub and/or 
substrate to illustrate how Ub transfer to substrate is mediated. The closest is a 
structure of the RING domain of BIRC7 bound to UbcH5B–Ub (Figure 1-19C) (PDB 
ID: 4AUQ) [66]. A structure of the RING domain of either cIAP bound to E2~Ub 
will be helpful in understanding how cIAPs mediate Ub transfer and illustrate 
similarities and differences to other RING E3-E2~Ub complexes. 
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Figure 1-19: Available structures of cIAP2. (A) Left: BIR3 domain of cIAP-2 
coloured cyan (PDB ID: 2UVL) [140]. Right: cIAP2 RING dimer coloured green. 
The dimer was generated using a symmetry mate. Zn2+ ions are shown as grey spheres 
(PDB ID: 3EB5). (B) cIAP2-UbcH5B (PDB ID: 3EB6) [77]. The RING is coloured 
as in A and the E2 is coloured magenta. (C) BIRC7-UbcH5B~Ub (PDB ID: 4AUQ) 
[66]. The two subunits of the RING dimer are shown in green and orange, UbcH5B in 
magenta, Ub in cyan and. Zn2+-ions are shown as grey spheres. 
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Objectives of the thesis 
 
RING E3s are the biggest family of E3s and are the major focus of my PhD thesis. 
Recently there has been an increase in the number of structural and biochemical 
characterisation studies on RING E3 mediated Ub transfer. There are several 
structures available that illustrate how RING E3s recruit E2~Ub and stabilise the 
RING domain-E2~Ub complex for optimal Ub transfer. RING E3s also recruit 
substrate and facilitate transfer of Ub from E2’s active site to a lysine residue on 
substrate. How RING E3s achieve these steps still remains elusive. In addition to the 
RING domain of RING E3s, there are also other factors that help to stabilise the 
RING domain-E2~Ub complex. The objectives of my thesis are as follows: 
 
1) To use structural and biochemical studies to elucidate the roles of non-covalent 
Ub in cIAP1-mediated Ub transfer. In 2015, our lab showed for the first time how 
UbB enhances RING-mediated E2~Ub transfer. We used a monomeric RING E3, 
RNF38, for this study. During my PhD, I aimed to crystallise a complex of cIAP1 
bound to UbcH5B–Ub and UbB. This study will help us to understand whether the 
mechanism of non-covalent binding is conserved in other RING E3s and in 
UbcH5 family of proteins.  
 
2) To determine whether non-covalent Ub binding mechanism is conserved in 
UbcH6. The UBC domain of UbcH6 is very similar to that of the UbcH5 family 
of E2s, so I aimed to investigate whether the UbcH6 family also exhibits non-
covalent binding of Ub to its backside. 
 
3) To assemble E3/E2~Ub/substrate complexes to study polyUb chain formation. 
How RING E3s transfer Ub to a lysine side chain on a substrate is still  unknown. 
In my PhD, I aimed to generate a substrate mimetic to understand how polyUb 
chain formation occurs. 
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Chapter 2 
 
 
Materials and Methods 
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2.1 Materials 
The c-DNA of full-length human c-Cbl and Cbl-b were purchased from Source 
BioScience. pGEX4T1 and pRSFDuet were purchased from GE Healthcare. Other 
than Ub fusion peptide, all plasmids were obtained from lab members. DNA 
polymerase and other cloning buffers and enzymes were purchased from Invitrogen. 
Dr. Gary Sibbet generated DH5α and BL21(DE3) competent cells. All expression 
vectors (pGEX4T1, pRSFDuet) obtained from lab members. GSH sepharose, Nickel 
agarose and glutathione were purchased from GE Healthcare.  
 
2.2 Methods 
2.2.1 Primer design and molecular cloning 
All the constructs were generated by standard polymerase chain reaction (PCR) using 
forward and reverse primers purchased from Integrated DNA Technologies and Pfu 
Ultra DNA polymerase from Stratagene. QIAquick PCR purification kit and 
QIAquick gel extraction kit from QIAGEN were used to purify PCR products. PCR 
product was ligated into appropriate vector by using Quick Ligase from NEB and 
subsequently transformed into DH5α competent cells. Positive clones were verified 
by automated sequencing at the Cancer Research UK Beatson Institute. All constructs 
and associated primers that I generated for studies in Chapters 3, 4, and 5 are listed in 
Table 2-1. For generation of Ub fused peptides for Chapter 5, multiple rounds of PCR 
were formed, where PCR product from each round of PCR was purified and used as 
the template for the next round of PCR (Figure 2-1). Verified clones were 
transformed into BL21 (DE3) competent cells for protein expression. 
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Figure 2-1: Generation of Ub fused peptide (Ub-peptide) using multiple rounds of 
PCR. F: forward primer, R: reverse primer, Rd1: round1, Rd2: round2 and Rd3: 
round3 
 
Table 2-1 Generation of protein expression constructs (UbcH5D, cIAP2(255-C) 
and all Ub-peptide constructs were generated by me. Other people in the lab 
generated all the other listed constructs) 
 
Construct Primers (5’ to 3’) Restriction 
site 
Vector Molecular 
weight 
(KDa) 
cIAP1 
(555-C) 
F: gaagatctatgcacaaaactgcctcccaaag BglII pGEX4T1  
 
~42 
R:cggaattcttaagagagaaatgtacgaac 
    agtacc 
EcoR1 
UbcH5A F: catgccatggcgctgaagaggattcag NCOI pRSFDuet  
 
~17 
R: cggaattcttacattgcatatttctgagtc 
    cattctc 
ECOR1 
UbcH5B F: cgggatccatggctctgaagagaatccac BamH1 
 
pRSFDuet  
 
~17 
R: cggaattcttacatcgcatacttctgagtcc ECOR1 
UbcH5C F: catgCCATGGcgctgaaacggattaa 
    taag 
NCOI pRSFDuet  
 
~17 
R: cgGAATTCtcacatggcatacttctgag 
     tcc 
ECOR1 
UbcH5D F: catgCCATGGcgttaaagcgtatccag 
     aaag 
NCOI pRSFDuet  
 
~17 
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R: cgGAATTCttacatagcatatttttgggt 
     ccattc 
ECOR1 
UbcH5BS22R F: ccagcacagtgtcgcgcaggtcctgttg BamH1 
 
pRSFDuet  
 
~17 
R: caacaggacctgcgcgacactgtgctgg ECOR1 
UbcH5BC85K F: cagtaatggcagcattaaacttgatattctac 
    gatcac 
BamH1 
 
pRSFDuet  
 
~17 
R: gtgatcgtagaatatcaagtttaatgctgcca 
     ttactg 
ECOR1 
UbcH5BC85S F:gtaatggcagcatttctcttgatattctacgatc NCO1 pRSFDuet  
 
~17 
R:gatcgtagaatatcaagagaaatgctgcca 
    ttac 
ECOR1 
UbcH5BQ20A F: gaccctccagcagcgtgttcagcagg BamH1 
 
pRSFDuet  
 
 
R: cctgctgaacacgctgctggagggtc ECOR1 ~17 
UbcH5BS108R F: ctcttgtccatctgtcgtctgttgtgtgatc BamH1 pRSFDuet  
 R:gatcacacaacagacgacagatggacaaga
g 
ECOR1 ~17 
Ubiquitin F: cgggatccatgcagattttcgtgaaaaccc BamH1 
 
pGEX4T1  
 
~10 
R: ccgctcgagttaaccaccacgaagtctca 
    acac 
Xho1  
Ubiquitin 
I44A 
F: cagcagagactggcctttgctggcaag BamH1 
 
pRSFDuet ~10 
R: cttgccagcaaaggccagtctctgctg Xho1  
UbcH6 43-C F: gaagatctaaactcctctccaccagcgcc BglII 
 
pRSFDuet ~17 
R:acgcgtcgacttatgtagcgtatctcttggtcc SalI 
UbcH6  
43-CS68R 
F: ccacctaattgccgtgctggtcccaa BglII 
 
pRSFDuet ~17 
R: ttgggaccagcacggcaattaggtgg SalI 
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cIAP2  
(255-C) 
F: cgggatcccatgctgcccgcttcaagacc BglII 
 
pRSFDuet ~42 
R: cggaattctcatgaaagaaatgtacgaactg 
     tacc 
ECOR1 
c-Cbl  
(47-435) 
F: cgggatccccgccggggacggtggaca 
    agaag 
BamH1 
 
pGEX4T1 ~45 
R: ccgctcgagttaatcaaacggatctaccacg 
    atggg 
Xho1 
Cbl-b 
(36-427)Y360F 
F: agttacacaggaacaatttgaattatattgtga BglII 
 
pGEX4T1 ~45 
R: tcacaatataattcaaattgttcctgtgtaact Xho1 
SMAC  
(56-C) 
F: catgccatggcggttcctattgcacagaaa 
    tcag 
Nco1 
 
pET23d ~25 
R:ccgctcgagatcctcacgcaggtaggcc 				tcctg	 Xho1 
Ub 
ΔGG 
F:cgggatccggtggctctatgcagattttcgtg    
aaaaccc 
BamH1 
 
pGEX4T1 
2TK 
~10 
R:atagtttagcggccgctcaacgaagtctca 
    acacaagatgaag 
Xho1 
Ub-ZAP70 F: RD1-3   
ctcaggggtgtatccatctgagttgagggtg     
gccgcacgaagtctcaacacaagatgaag 
 
BamH1 pGEX4T1 ~12 
R: RD1  ggtacgctgccgctggccgca 
cgaagtctcaacacaagatgaag  
R: RD2 gctcaggggtgtatccatctg 
agttgagggtaccgctgccgctggc  
R: RD3  cggaattctcagtggtgatgatgg 
tgatgtgctggctcaggggtgtatccatctgagt 
EcoR1 
Ub-Src F: RD1-3 ctcaggggtgtatccatctgagt 
gaggtggccgcacgaagtctcaacacaagatg
aag  
BamH1 pGEX4T1  
 EcoR1 ~12 
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R: RD1-3  aggcggctgccaccgctac 
cgccgctgcccccggcgcggcacgaagtctca
acacaa 
R: RD2 tgatggccctggcgcgcggtata 
ttcgttatcttcaatcaggcggctgccaccgc 
R: RD3 cggaattctcagtggtga 
tgatggtgatggccctggcgcgcggtatattcgt 
 
Ub-cMET F:  RD1- 3 
ctcaggggtgtatccatctgagttgagggtg 
gccgcacgaagtctcaacacaagatgaag 
 
BamH1 pGEX4T1 ~12 
R: RD1  
ttgctgctgccaccgctaccgccgctgcca 
Cccggggccgcacgaagtctcaacacaa 
R: RD2  
ggtgatgttccggaaaggtcgcgcgataa  
tccacgctttcgttgctgctgccacc 
R: RD3  
cggaattctcagtggtgatgatggtgatgtt  
ccggaaaggtcgcgcgataat 
EcoR1 
cIAP1 
(555-C) 
F: gaagatctatgcacaaaactgcctcccaaag BglII 
pGEX4T1  
 
~42 
R: cggaattcttaagagagaaatgtacg 
     aacagtacc 
EcoR1 
UbcH5A 
F: catgccatggcgctgaagaggattcag NCOI 
pRSFDuet  
 
~17 
R: cggaattcttacattgcatatttctgagt 
     ccattctc 
ECOR1 
UbcH5B 
F: cgggatccatggctctgaagagaatccac 
BamH1 
 
pRSFDuet  
 
~17 
R: cggaattcttacatcgcatacttctgagtcc ECOR1 
UbcH5C 
F:  catgCCATGGcgctgaaacggat 
      taataag 
 
NCOI 
pRSFDuet  
 
~17 
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R:  cgGAATTCtcacatggcatacttctg 
      agtcc 
              
ECOR1 
UbcH5D 
F:  catgCCATGGcgttaaagcgtatcca 
     gaaag 
NCOI 
pRSFDuet  
 
~17 
R:  cgGAATTCttacatagcatatttttggg 
      tccattc 
ECOR1 
UbcH5BS22R 
F: ccagcacagtgtcgcgcaggtcctgttg 
BamH1 
 
pRSFDuet  
 
~17 
R: caacaggacctgcgcgacactgtgctgg ECOR1 
UbcH5BC85K 
F: cagtaatggcagcattaaacttgatattct 
     acgatcac 
BamH1 
 pRSFDuet  
 
~17 
R: gtgatcgtagaatatcaagtttaatgctgc 
     cattactg 
ECOR1 
UbcH5BC85S 
F: gtaatggcagcatttctcttgatattctac 
     gatc 
NCO1 
pRSFDuet  
 
~17 
R: gatcgtagaatatcaagagaaatgctgcc 
     attac 
ECOR1 
UbcH5BQ20A 
F: gaccctccagcagcgtgttcagcagg 
BamH1 
 
pRSFDuet  
 
 
R: cctgctgaacacgctgctggagggtc ECOR1 ~17 
UbcH5BS108R 
F: ctcttgtccatctgtcgtctgttgtgtgatc BamH1 
pRSFDuet  
 
R: gatcacacaacagacgacagatggaca 
    agag 
ECOR1 
~17 
Ubiquitin 
F: cgggatccatgcagattttcgtgaaaaccc 
BamH1 
 pGEX4T1  
 
~10 
R: ccgctcgagttaaccaccacgaagtctca 
     acac 
Xho1 
 
Ubiquitin 
I44A 
F: cagcagagactggcctttgctggcaag 
BamH1 
 pRSFDuet 
~10 
R: cttgccagcaaaggccagtctctgctg Xho1  
UbcH6 43-C F: gaagatctaaactcctctccaccagcgcc 
BglII 
 
pRSFDuet 
~17 
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R: acgcgtcgacttatgtagcgtatctcttg 
     gtcc 
SalI 
UbcH6  
43-CS68R 
F: ccacctaattgccgtgctggtcccaa 
BglII 
 pRSFDuet 
~17 
R: ttgggaccagcacggcaattaggtgg SalI 
cIAP2 
 (255-C) 
F: cgggatcccatgctgcccgcttcaagacc 
BglII 
 
pRSFDuet 
~42 
R: cggaattctcatgaaagaaatgtacgaactg 
     tacc 
ECOR1 
c-Cbl  
(47-435) 
F: cgggatccccgccggggacggtggacaa 
     gaag 
BamH1 
 
pGEX4T1 
~45 
R: ccgctcgagttaatcaaacggatctaccac 
     gatggg 
Xho1 
Cbl-b 
(36-427)Y360F 
F: agttacacaggaacaatttgaattatattgtga 
BglII 
 pGEX4T1 
~45 
R: tcacaatataattcaaattgttcctgtgtaact Xho1 
SMAC  
(56-C) 
F: catgccatggcggttcctattgcacagaaa 
    tcag 
Nco1 
 
pET23d 
~25 
R: ccgctcgagatcctcacgcaggtaggcct 
     cctg 
Xho1 
UbΔGG 
F: cgggatccggtggctctatgcagattttcg 
     tgaaaaccc 
BamH1 
 pGEX4T1 
2TK 
~10 
R:  atagtttagcggccgctcaacgaagtctc 
       aacacaagatgaag 
Xho1 
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2.2.2 Expression and purification of proteins 
Plasmids of protein of interests were transformed into BL21 Gold (DE3) competent 
cells. Bacterial culture were grown at 37 °C with suitable antibiotics (ampicillin or 
kanamycin) at 100 mg/L or 50 mg/L, respectively. Cells were induced at an OD 
A600nm of 0.8 with 0.2 mM isopropyl β-D-thiogalactopyranoside (IPTG) at 20 °C 
overnight. Cells were harvested by spinning them at 4000 rpm at 4 °C for 15 minutes. 
Cells were then resuspended into resuspension buffer (wash buffer used in first step 
for purification) with 2.5 mM phenylmethylsulphonyl fluoride (PMSF). Before lysing 
cells, 10 µg DNase I was added to 100 ml lysate to reduce the viscosity of sample and 
prevents blocking microfluidizer. Cells were lysed using microfluidizer M-110P at 
15-18000 psi. Cells were passed twice  through the microfluidizer. Lysed cells were 
then centrifuged twice at 20,000 rpm for 30 minutes at 4 °C in Beckman Ultra high-
speed centrifuge. Clear lysates were then purified by either glutathione sepharose 
(GSH) or Ni2+ affinity chromatography depending on the tag used using gravity 
column. GST or His-tag was subsequently removed by treatment with thrombin or 
TEV protease and further purified by ion exchange chromatography followed by size 
exclusion chromatography on AKTA FPLC. Purified protein of interest was then 
concentrated using Amicon Ultra centrifugal filter units and snap-frozen in liquid 
nitrogen and stored at -80 °C for future crystallisation and biochemical studies. 
Protein concentrations were measured by using Bradford assay with bovine serum 
albumin (BSA) as standard [141]. Concentration of Ubiquitin and Ub-peptide were 
measured at A280  using Denovix DS-11 spectrophotometer 
 
Con(mg/ml) = A280*MW(Da)  ≈     A280 
                           Ext.Co                      0.16 
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Buffers used in for affinity purification and gel filtration chromatography: 
Chromatography Buffers 
GSH-affinity Wash buffer: 50 mM Tris-HCl 7.6, 0.2 M 
NaCl, 1 mM DTT 
Elution buffer: 50 mM Tris-HCl 8.0, 0.2 
M NaCl, 5 mM DTT and 10 mM GSH 
Ni2+ affinity Wash buffer: 50 mM Tris-HCl 7.6, 0.15 
M NaCl, 15 mM imidazole and 5 mM 
BME 
Size exclusion 50 mM Tris-HCl 7.6, 0.15 M NaCl and 1 
mM DTT 
 
The list of proteins purified is listed below in Table 2-2. The table describes which 
protein is purified and their contributors. Those proteins that I purified are described 
in details below. 
Table 2-2: List of proteins purified  
Protein Contributors  
cIAP1(555-C) See Section 3.2.1 
UbcH5A, UbcH5C, UbcH5D See Section 2.6 
UbcH5B See Section 2.5 
UbcH6 WT and S68R See Section 4.2.1 
UbcH5BC85K–Ub,UbcH5BS22R–Ub, 
UbcH5BC85–S,N77A 
See Section 2.7 
Arabidopsis thaliana Uba1 See Section 2.4 
Ub-peptide (Ub-ZAP70, Ub-cMet, Ub-Src) See Section 5.2.4 
Pc-Cbl, and pCbl-b See Section 2.3 
cIAP2(255-C) See Section 2.8 
cIAP1(260-C) Purified by Mads Gabrielsen 
UbcH5B variants S108R and Q20A Purified by Lori Buetow and Hao Dou 
Ubiquitin variant (I44A) and UbΔGG Purified by Lori Buetow and Hao Dou 
SMAC (56-C) Purified by Lori Buetow 
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2.3 Purification of ubiquitin 
Histidine tagged ubiquitin was cloned into RSFDuet vector with TEV cleavage site. 
Cells were grown harvested and lysed as mentioned in Section 2.2.2. Lysed cells were 
purified onto 30ml Ni2+ beads on gravity column. Buffers used for purification are 
mentioned below:  
Wash buffer 50mM Tris-HCl pH 7.6, 0.2M NaCl, 
20mM immidizole pH8.0 and 5mM β-
mercaptoethanol 
Elution buffer 50mM Tris pH 7.6, 0.2M NaCl, 200mM 
immidizole pH8.0 and 5mM β-
mercaptoethanol 
 
Eluted protein was mixed with TEV protease at 1:50 protein ratio (TEV: protein) to 
remove His tag, The mixture was dialysed against 50 mM Tris-HCl pH 7.6, 0.15 M 
NaCl and 5 mM β-mercaptoethanol at room temperature overnight. Next day, protein 
was passed back onto 10ml Ni2+ beads to remove uncleaved protein and was further 
purified by gel filtration column (S75 16/60). Eluted fractions was concentrated and 
snap freezed at -80°C.  
2.4 Protein purification of pc-Cbl and pCbl-b 
c-Cbl47-435 Y368F was previously cloned into pGEX4T1 His-GST vector with a 
thrombin cleavage site by my colleague. It was co-transformed into BL21 Gold (DE3) 
with mouse Src84-526, which was cloned into pRSFDuet with a N-terminal His-MBP 
tag. A single colony was used to inoculate 200 mL of LB media containing 100 mg/L 
ampicillin and 25 mg/L kanamycin and the culture was grown at 37 °C overnight. 
Next day, the overnight culture was used to inoculate 60 litres of LB media containing 
100 mg/l ampicillin and 25 mg/l kanamycin and the culture was grown at 37 °C and 
induced as described in the method above. Before lysing cells 2 mM sodium 
orthovanadate (Sigma) was added to inhibit protein phosphotyrosyl phosphatases and 
prevent dephosphorylation. pCbl was purified using Ni2+ affinity chromatography 
using 25 ml Ni2+ beads on a gravity column. Eluted protein was then stirred with 
GSH-sepharose beads for one hour and then washed and eluted. Protein was then 
treated overnight with thrombin protease in 1:100 thrombin:protein ratio (mg ratio) in 
presence of 10 mM CaCl2 at 4 °C overnight (Figure 2-2A). Next day, cleaved protein 
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was passed through 25 ml Ni2+ beads column to get rid off His-GST tag and 
subsequently applied on an anion exchange chromatography (20 mL Source Q 
column) to separate phosphorylated c-Cbl from non-phosphorylated c-Cbl (Figure 2-
2B). Buffers used for Source Q column are mentioned below. Phosphorylated c-CBL 
was pooled, concentrated using Amicon Ultra centrifuge and further passed through 
size exclusion chromatography S75 10/300 for final buffer exchange (Figure 2-2D). 
Fractions containing pure pCbl were pooled and concentration was determined. Then 
pCbl was aliquoted in small volume, snap-frozen and then stored at -80 °C for 
crystallisation (Figure 2-2). 
 
Chromatography Buffers 
20 ml Source Q  Buffer A: 50 mM Tris-HCl pH 8.5 and 1 
mM DTT 
Buffer B: 50mM Tris-HCl pH 8.5, 1 M 
NaCl and 1 mM DTT 
Size exclusion chromatography 
S75 10/300 
50 mM Tris-HCl pH 7.6, 0.15 M NaCl 
and 1 mM DTT 
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Figure 2-2: Purification steps of pCbl. (A) Gel run after thrombin cleavage. Lane 1 
shows sample after Ni2+ and GSH-sepharose affinity purification and lane 2 shows 
sample in lane 1 treated with thrombin overnight followed by Ni2+ pass back. This 
sample was applied onto 20 mL Source Q column. (B) Chromatogram showing 
elution profile of pCbl on 20 ml source Q column chromatography. (C) SDS-PAGE 
showing the purity of fractions from (B). Fractions containing pure pCbl were pooled, 
concentrated and applied on a SD75 gel filtration column. (D) Chromatogram 
showing elution profile of pCbl on SD75 gel filtration chromatography. (E) SDS-
PAGE showing the purity of fractions from (D). Single band equivalent of pCbl size 
can be seen. Fractions B1-C5 were pooled and concentrated and then aliquoted, snap-
frozen and stored at -80 °C. 
 
2.5 Purification of Arabidopsis thaliana Uba1 (developed by Danny 
Huang) 
 
Untagged Arabidopsis thaliana Uba1 was cloned in pET23d vector. 24 litres of E. 
coli culture was grown at 37 °C LB media with 100 mg/l ampicillin. Cells were 
induced, harvested and lysed as described in the methods above. GST tagged Ub was 
cloned into pGEX4T1 vector was also expressed similarly as mentioned above. 
Lysates from both Uba1 and GST tagged Ub were mixed together along with 2.5 mM 
MgCl2 and 2.5 mM ATP. The mixture of lysate was stirred for two hours at 4 °C. 
Uba1~GST-Ub was purified using GSH-sepharose affinity column and Uba1 was 
released from GSH-sepharose column by incubating with wash buffer containing 20 
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mM DTT. Uba1 was further purified by anion exchange chromatography (20ml 
Source Q column). Protein eluted from Source Q was pooled, aliquoted, snap-frozen 
and stored at -80 °C in buffer containing 50 mM Tris-HCl pH 7.6, 0.15 M NaCl and 1 
mM DTT (Figure 2-3). 
 
 
Figure 2-3: Purification of Uba1. (A) Chromatogram of Uba1 after 20 ml Source Q 
column. (B) SDS-PAGE showing the purity of Uba1. Lane 1 is after elution from 
GSH-sepharose column and Lane 2 is from the peak fraction in 20 mL source Q 
column. 
 
2.6 Purification of UbcH5B 
Untagged UbcH5B was transformed and expressed into BL21 DE3 E.Coli cells. Cells 
were grown and harvested and lysed as mentioned in above section 2.2.2. Lysate was 
then diluted with 50mM MES buffer pH 6.5 with 1mM DTT, the lysate turned milky 
on dilution. Now the lysate was loaded on 20ml sulphopropyl (SP) sepharose beads 
on gravity column. After loading the lysate, column was washed with 50mM MES pH 
6.5, 50mM NaCl and 1mM DTT. Protein was eluted with 50mM MES pH 6.5, 0.2 M 
NaCl and 1 mM DTT. Eluted protein was then diluted with 50mM MES pH 6.5 and 
1mM DTT to dilute the salt concentration. Now, diluted protein was loaded onto 20 
ml Source S column. Buffers used for Source S column are mentioned below. Eluted 
protein was then concentrated with 50mM Tris 7.6, 0.2M NaCl and 1mM DTT, since 
UbcH5B is unstable at low salt concentration. Concentrated protein was then loaded 
onto size exclusion S75 column. Buffer used for gel filtration is mentioned in Section 
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2.3. The eluted protein was snap freezed and stored at -80° C (see Figure 2-4 for 
purification).   
Chromatography Buffers 
20 ml Source S Buffer A: 50 mM MES pH 6.5, 1mM 
DTT 
Buffer B: 50mM MES pH6.5, 0.2M 
NaCl, 1mM DTT 
Size exclusion chromatography 
S75 10/300 
50 mM Tris-HCl pH 7.6, 0.15 M NaCl 
and 1 mM DTT 
 
 
 
Figure 2-4: Protein purification of UbcH5B WT. (A) SDS gel after 20ml SP 
sepharose gravity column (B) chromatogram showing elution after 20ml Source S 
column (C) chromatogram after gel filtration SD75 column (D) SDS gel for fractions 
eluted after SD75 gel filtration column. 
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2.7 Purification of UbcH5A, UbcH5C and UbcH5D 
Untagged UbcH5A, C and D were cloned into pRSFDuet vector. They were then 
transformed and expressed into BL21 DE3 E.Coli. cells. Method for growth, 
expression, harvesting and lysing cells is same as described in Section 2.2. Lysate was 
purified using 20ml SP sepharose beads on gravity column. Buffers used were same 
as that used in purification of UbcH5B. Eluted protein was then purified using on 20 
ml Source S column using cation exchange chromatography followed by gel filtration 
chromatography using S75 column. Buffers used for Source S and S75 column were 
same as that used in UbcH5B WT. Protein eluted from S75 column were concentrated 
and run on SDS gel to check purity (Figure 2-5).  
 
Figure 2-5: Protein purification of UbcH5A, UbcH5C and UbcH5D. (A) SDS gel 
for fractions eluted from S75 column for UbcH5A (B) SDS gel for fractions eluted 
from SD75 column for UbcH5C (C) SDS gel for fractions eluted from SD75 column 
for UbcH5C 
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2.8 Purification of UbcH5B–Ub  
UbcH5B~Ub thioester linkage is not very stable and rapidly dissociates into E2 and 
Ub in presence of E3s. To generate stable UbcH5B–Ub linkage, our lab has mutated 
UbcH5B’s catalytic Cys85 to Lys (C85K) to generate stable isopeptide linkage or 
(C85S) to generate stable oxy-ester linkage [66]. During my PhD, I used the method 
developed in lab to generate UbcH5B–Ub variants (UbcH5BC85K–Ub, UbcH5BS22R–
Ub, UbcH5BC85S,N77A–Ub). Below (section 2.5.1) I have described method of 
purifying UbcH5BC85K–Ub in detail. Other UbcH5B–Ub variants were purified in 
similar manner. 
 
2.8.1 Purification of UbcH5BC85K~Ub 
Untagged UbcH5BC85K, His tagged Ub and untagged Uba1 were purified separately as 
explained in method section. Individual protein was thawed and centrifuged at 13000 
rpm for 10 minutes at 4° C. Charging reaction was setup as follow. I charged 
approximately 120 µM of untagged UbcH5BC85K by adding 2 molar excess of His-Ub 
compared to UbcH5BC85K. To this, I added 0.1M Tris pH 9.0 followed by 5-6 µM of 
Arabidopsis Uba1 for every 6 mg of UbcH5BC85K and 10mM MgCl2. The reaction 
was started by adding 10mM ATP pH ~7-8.  The reaction was allowed to sit at 30 °C 
for 12-16 hrs. Charging reaction was analysed by SDS-PAGE (Figure 2-6A). The 
reaction was stopped by adding 5 mM β-mercaptoethanol and then purified by Ni2+-
affinity column. Eluted fractions were pooled (Figure 2-6B) and mixed with TEV 
protease at 1:50 protein ratio (TEV: protein) to remove His tag, The mixture was 
dialysed against 25 mM Tris-HCl pH 7.6, 0.15 M NaCl and 5 mM β-mercaptoethanol 
at 4 °C overnight. Next day, TEV cleavage was analysed by SDS-PAGE (Figure 2-
6C). 
The cleaved protein was passed back onto 10 ml Ni2+ gravity column to remove 
uncleaved protein. Flow through was collected and diluted with 50 mM MES, pH 6.0, 
1 mM DTT to bring down the pH of buffer and then further purified using 20 ml 
Source S column (Figure 2-6D). Fractions A7-B7 containing UbcH5BC85K–Ub were 
pooled (Figure 2-6E) and concentrated using method as explained in method section 
2.2.2 for concentrating proteins. Concentrated protein was centrifuged at 13000 rpm 
at 4 °C for 10 minutes to spun down any pellet/aggregate after concentrating protein. 
Concentrated protein was then purified using 10/300 SD75 gel filtration column in 
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buffer containing 50 mM HEPES, pH 8.0, 0.15 M NaCl and 1 mM DTT. Fractions 
containing pure UbcH5BC85K–Ub were pooled, concentrated, aliquoted, snap-frozen 
and stored at -80 °C. 
 
 
Figure2-6: Protein purification steps of UbcH5BC85K–Ub. (A) SDS gel showing 
before (lane 1) and after (16-20 hrs; lane 2) setting up the reaction to charge 
UbcH5BC85K with His-Ub. (B) SDS-gel showing Ni2+ pull down of UbcH5BC85K~His-
Ub. Lane 1, 2 and 3 are fractions 1, 2 and 3 of 10ml each after eluting from 10ml Ni2+ 
gravity column. Only His-Ub and UbcH5BC85K~His-Ub was retained with some trace 
amount of Uba1. (C) SDS gel showing UbcH5BC85K~His-Ub before (lane 1) and after 
(lane 2) TEV treatment. (D) 20 ml Source S chromatography of UbcH5BC85K~Ub. 
Chromatogram showing a single peak of eluted protein. (E) SDS gel showing proteins 
from fractions A3 to B10 in (D). 
 
2.9 Protein purification of cIAP2 (255-C) 
 
cIAP2(255-C) construct was cloned into pGEX4T1 His-GST vector with TEV 
cleavage site (vector modified and designed by Lori Buetow). Cells were grown 
harvested and lysed as mentioned in Section 2.2.2. Lysed cells were purified onto 
20ml GSH sepharose beads on gravity column. Buffers used are mentioned in Section 
2.2.2. Eluted protein was mixed with TEV protease at 1:50 protein ratio (TEV: 
protein) to remove His-GST tag, The mixture was dialysed against 25 mM Tris-HCl 
pH 7.6, 0.15 M NaCl and 5 mM β-mercaptoethanol at 4 °C overnight. Next day, 
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protein was passed back onto 10ml Ni2+ beads to remove uncleaved protein and was 
further purified by gel filtration column (S75 16/60). Eluted fractions was 
concentrated and snap freezed at -80°C (Figure 2-7).  
 
                                  
 
 
 
Figure 2-7: Protein purification of cIAP2(255-C). Lanes 1,2 and 3 are protein 
fractions run after GST pull down. Lane 4 is protein marker and lane 5 is concentrated 
protein after TEV cleavage, Ni2+ pass back and gel filtration run 
 
2.10 Crystallisation 
2.10.1 cIAP1R-UbcH5BC85K–Ub-UbB complex 
 cIAP1R-UbcH5BC85K–Ub-UbB complex was assembled by mixing cIAP1R (8.5 
mg/ml) UbcH5BC85K–Ub (20mg/ml) and Ub (100mg/ml) at 1:1:1.2 molar ratio. Initial 
crystallisation screen was performed using sitting drop vapour diffusion technique 
with screens from crystallisation kits JCSG+, PEGs, Proplex, Index, Morpheus, 
Ammonium Sulphate, PACT (bought from Molecular Dimensions, Hampton 
Research and Qiagen) at 19 °C  where each drop contains equal volume (200  µL) of 
protein and reservoir solution. Crystals was obtained and optimised in condition 
containing 0.2M ammonium fluoride and 15% (w/v) PEG 3350. The crystals were 
harvested and flash frozen in 0.2 M ammonium fluoride, 18% (w/v) PEG 3350 and 
20% (v/v) ethylene glycol.  
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2.10.2 Data collection and processing 
Data were collected at beamlines I03 at Diamond Light Source (DLS) and processed 
using xia2 pipeline [142]. The data were integrated with automated XDS (Kabsch, 
2010) including POINTLESS (Evans, 2006), AIMLESS (Evans and Murshudov, 
2013), CCP4 (Winn et al., 2011. Initial phases of cIAP1R-UbcH5BC85K–Ub-UbB 
complex were obtained by molecular replacement with PHASER using UbcH5B and 
Ub from PDB 3ZNI and cIAP2 RING from PDB 3EB6 . All models were built in 
COOT (Emsley and Cowtan, 2004) and refined using PHENIX (Adams et al., 2002). 
cIAP1R-UbcH5BC85K–Ub-UbB complex was refined to resolution of 1.7 Å. The final 
model contains one copy of cIAP1R (chain A, residues 556-C), one copy of 
UbcH5BC85K (chain C residues 1-147), one copy of UbB (chain B residues 1-72) and 
one copy of UbD (chain D, residues 1-76). All figure models were generated using 
PYMOL. 
2.11 Lysine discharge assays 
Lysine discharge assays were performed to monitor rate of E2~Ub transfer in the 
presence and absence of excess of UbΔGG (UbΔGG lacks C terminal diglycine tail, 
and therefore cannot be charged by E1). In a typical lysine discharge assay E2 is 
charged with equimolar Ub with reaction mixture containing E1 and Ub for about 15-
20 minutes (depending on which E2 is used) at 23 °C. The charging is then stopped 
by adding mixture of EDTA and apyrase. The reaction is initiated by adding mixture 
of E3 and lysine, with or without excess of UbΔGG and is then stopped at specific 
time points by mixing with SDS loading buffer. Assays performed using radio 
labelled Ub was processed and visualised using autoradiography, whereas non-
labelled Ub were run on SDS gel and visualised using coomassie stain. The graphical 
view of what happens in lysine discharge assay is illustrated below in Figure 2-8. 
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Figure 2-8: Lysine discharge assay. E2 is charged with equimolar of Ub for 15 
minutes. The charge is then stopped by adding EDTA and apyrase. A mixture 
containing lysine and E3 was then added to initiate E2~Ub discharge reaction. 
Discharge is monitored by the disappearance of E2~Ub band on SDS-PAGE. When 
Ub is labelled with 32P, the gel is dried and analysed by autoradiogram. 
 
Labelling Ub with radioactive 32P 
2TK-Ub was used for labelling, which was expressed and purified by Lori Buetow. 
Radiolablled 2TK Ub was generated using method as described [143]. The reaction 
mixture used for labelling Ub contained 10x buffer made up of 500 mM Tris 7.6, 50 
mM ATP pH 7-8, 50mM MgCl2; 2TK Ub (I usually made a stock of 200 µM Ub); 
[γ32P]-ATP (NEG502Z250UC; Perkin Elmer); 0.5 µl of 2,500 U/ml protein kinase A 
(PKA) enzyme and water. This reaction mixture is allowed to incubate for 2 hours at 
room temperature before using it in the assays. 
2.11.1 Lysine discharge assays with UbcH5B~Ub 
 For 32P-Ub assays shown in Section 3.2.2, Figure 3-3, UbcH5 variants (12.5 µM) 
were charged with Arabidopsis Uba1 (1 µM) and 32P-Ub (12.5 µM) for 15 min at 
23 °C as described previously (Buetow et al., 2016) including BSA (1mg/ml). 
Charging was stopped by incubating the reaction with 0.01 U/ml apyrase and 50 mM 
EDTA at 23 °C. The 32P-Ub lysine discharge assays were initiated by addition of 
reaction mixture containing 50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 1 mg/ml BSA, 
20 mM L-lysine (in presence of E3) and 500 nM cIAP1R in presence of UbΔGG (300 
µM). Reactions were stopped with SDS loading buffer at specified time points and 
resolved by SDS-PAGE. Reactions were dried and visualised by autoradiography. 
 
2.11.2 Lysine discharge assays with UbcH6 (43-C)~Ub 
For lysine discharge assays shown in Figure 4-6, UbcH6 (43-C) variants (WT and 
S68R) were charged equimolar with 32P-Ub as described above for 20 min at 23 °C. 
The reaction was initiated with different concentration of UbΔGG  (0, 20 µM, 300 
µM and 1mM UbΔGG) in presence of reaction mixture containing 50mM Tris –HCl 
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pH 7.6, 150 mM NaCl, 1mg/ml BSA, 20 mM L-lysine and 500 nM CAIP1R. 
Reactions were stopped with SDS loading buffer at specified time points and resolved 
by SDS-PAGE. Reactions ere dried and visualised by autoradiography. 
 
2.11.3 Lysine discharge assay with UbcH6(43-C)~Ub using 
ubiquitinated cIAP1 
For lysine discharge assay using ubiquitinated cIAP1 (260-C) shown in Figure 4-8, 
first reaction was set up for autoubiquitination of cIAP1. This reaction mixture 
contained 0.5 µM of cIAP1 (260-C), 5 µM Ub, 50 mM Tris-HCl pH 7.6, 50 mM 
NaCl, 5 mM MgCl2 , 5 mM ATP, 1mM DTT, 0.3 U/ml inorganinc pyrophosphatase, 
0.3 U/ml creatine  kinase and  5 mM creatine phosphate. The reaction was incubated 
at 23°C for 2.5 hours. Adding 30 mM EDTA and 0.01 U/mL of apyrase stopped 
reactions. This reaction was then used to initiate lysine discharge assays. UbcH6 (43-
c) WT and S68R was charged similarly as described above, and discharge assay was 
initiated with ubiquinated cIAP1. Reactions were stopped with SDS loading buffer at 
specified time points and resolved by SDS-PAGE. Reactions ere dried and visualised 
by autoradiography. 
 
2.11.4 Non-radioactive lysine discharge assays 
 For the non-radioactive lysine discharge assays shown in Figures 3-6 to 3-10 and 3-
12, assays were performed using wild-type non-radiolabelled Ub. UbcH5 variants 
(12.5 µM). For Figure 3-12, UbcH5A, B, C and D were charged with Arabidopsis 
Uba1 (1 µM) and Ub (12.5 µM) for 15 min at 23 °C as described previously in above 
section including BSA (1mg/ml). Charging was stopped by incubating the reaction 
with 0.01 U/ml apyrase and 50 mM EDTA at 23 °C. The lysine discharge assays were 
initiated by addition of reaction mixture containing 50 mM Tris–HCl, pH 7.6, 150 
mM NaCl, 1 mg/ml BSA, 20 mM L-lysine and 500 nM cIAP1R in presence and 
absence of 300 µM UbΔGG. . Whereas Figures 3-6 to 3-9 are lysine discharge assays 
of UbcH5B, cIAP1R and Ub variants performed under similar conditions as 
mentioned above, all in presence of UbΔGG. For Figure 3-9, UbcH5B Q20A mutant 
was charged and assay was performed with and without excess of Ub. Gels were 
visualised and stained with InstantBlue (Expedeon). 
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2.12 Ubiquitination assays 
Ubiquitination assays were carried out using radiolabelled 32P 2TKUb as mentioned 
earlier in Section 2.7. The labelling of Ub and charging of E2 was exactly same as 
mentioned above in Section 2.7 and 2.7.2. I performed autoubiquitination of cIAP1 
and cIAP2 shown in Figure 4-6A,B and Figure 4-8 respectively. Similarly, I 
performed SMAC substrate ubiquitination, shown in Figure 4-6C. In 
autoubiquitination assay charged E2~Ub transfer Ub onto E3’s lysine sites and form 
polyUb chains, whereas in substrate ubiquitination Ub is transferred from charged 
E2~Ub onto substrate’s lysine sites. Graphical view of what happens in a typical 
autoubiquitination and substrate ubiquitination assay is shown in figure below. 
 
Figure 2-9: Ubiquitination assay. (A) Autoubiquitination of E3s. Charged E2 would 
transfer Ub onto lysine site on E3 and form polyUb chain on E3. (B) Substrate 
ubiquitination. Charged E2 in presence of E3 would transfer Ub to substrate 
preferentially forming polyUb chain on substrate. 
 
2.12.1 Autoubiquitination of cIAP1 and cIAP2 
Autoubiquitination of cIAP1 (260-C) and cIAP2 (255-C) as shown in Figure 4-7A,B 
and 4-9A,B respectively were performed.in presence of 50 mM Tris-HCl, pH 7.6, 50 
mM NaCl, 5 mM MgCl2, 5 mM ATP, 1mM DTT, 0.3 U/ml inorganic 
pyrophosphatase, 0.3 U/ml creatine kinase and 5 mM creatine phosphate, 1 µM 
Arabidopsis Uba1, 5 µM UbcH6 variants, 50 µM 32P-Ub and 2.5 µM E3. Before 
adding E3s, the reaction mixture was allowed to charge for 20 minutes at 23°C. The 
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reactions were stopped with 2X loading buffer, resolved by SDS-PAGE, dried and 
visualised by autoradiography.  
 
2.12.2 SMAC substrate ubiquitination by cIAP1 
SMAC substrate ubiquitination was shown in Figure 4-7C was performed in presence 
of 50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 5 mM MgCl2, 5 mM ATP, 1mM DTT, 0.3 
U/ml inorganic pyrophosphatase, 0.3 U/ml creatine kinase and 5 mM creatine 
phosphate, 1 µM Arabidopsis Uba1, 5 µM UbcH6 variants, 50 µM 32P-Ub , 2.5 µM 
cIAP1 and 5 µM SMAC. As discussed in Section 2.8.1, UbcH6 was precharged for 20 
minutes at 23°C before adding mixture of SMAC and cIAP1. The reactions were 
stopped with 2X loading buffer, resolved by SDS-PAGE, dried and visualised by 
autoradiography. 
 
2.12.3 Ub-peptide substrate ubiquitination 
Ub-peptide substrate ubiquitination shown in Figures 5-9 and 5-10 were performed in 
presence of 50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 5 mM MgCl2, 5 mM ATP, 1mM 
DTT, 0.3 U/ml inorganic pyrophosphatase, 0.3 U/ml creatine kinase and 5 mM 
creatine phosphate, 0.1 µM Arabidopsis Uba1, 2 µM UbcH5B, 0.5 µM pc-Cbl and 50 
µM Ub-peptide. The reactions were stopped with 2X loading buffer and 1mM DTT. 
Gels were visualised and stained with InstantBlue (Expedeon). 
 
2.13 Surface plasmon resonance (SPR) 
Binding of UbB to UbcH5B and UbcH5B–Ub in presence and absence of cIAP1R was 
analysed by SPR (See section 3.2.2). SPR is a method of determining biomoleuclar 
interactions (protein-protein, protein-ligand, DNA-protein etc.) [144]. In SPR , the 
sensor surface forms  floor of a small flow cell, through which solution passes under 
continuous flow. To detect interaction one molecule (ligand) is immobilised onto the 
sensor surface. A thin layer of gold on the chip facilitates conductivity. Its binding 
partner (the analyte) is injected into sample buffer through the flow cell (Figure 2-10). 
In our lab, we use Biacore T200 instrument from GE healthcare for SPR analysis. The 
instrument uses detection system from Biacore T200 control software and is 
controlled by a PC. The anti-GST sensor chip used in the experiments were also 
purchased from GE healthcare. Buffer used during experiment contained 25mM Tris-
	 73	
HCl pH 7.6, 150mM NaCl, 0.005% tween 20 and 1mM DTT. In the performed 
experiments GST tagged cIAP1R was immobilised on the chip and UbcH5B variants 
(WT and S22R), UbcH5B–Ub variants (UbcH5BC85K–Ub and UbcH5BS22R–Ub) with 
and without excess of Ub were flown as analyte to measure the binding. SPR 
experiments shown in chapter 3 were performed by Dr. Gary Sibbet, whereas 
experiments shown in chapter 4 were preformed by me. 
 
Figure 2-10: SPR experimental set up. SPR helps in detecting variations in 
refractive index in the near proximity of the sensor chip surface. It is observed as 
shadow in the light reflected from the surface. Change in angle is determined by mass 
of surface. Figure adapted from Cooper (2002). 
 
2.14 Nuclear Magnetic Resonance (NMR) 
Nuclear magnetic resonance (NMR) is a powerful technique to study protein-protein 
interactions and mapping protein-binding surface in solution. Apart from X-ray 
crystallography, NMR has been used extensively in the past two decades to 
understand protein structures and its interactions. Earlier solving protein structure 
using NMR was limited due to low sensitivity of NMR spectrum and complex size of 
biomolecules. But with recent advancement in spectrometer design, data collection 
and analysis, it has emerged as a powerful technique in solving protein structures. 
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Apart from determining protein structures it has many advantages over other 
techniques to study protein-protein interactions. The biggest advantage of using NMR 
is that one can study biomolecules under natural physiological conditions [145]. I 
have used NMR technique to study interaction between Ub and UbcH6’s backside 
surface. My colleague, Mark Nakasone performed all NMR experiments. 
All NMR experiments were performed at 23°C on Bruker Avance III 600 
spectrometer equipped with three channel ceyoprobe. All the samples were in 25mM 
sodium phosphate buffer pH 7.0, 100mM NaCl containing 0.02% NaN3 and 5% D2O. 
The data was processed using TopSpin v2.1 (Bruker Biospin Inc) and analysed using 
in-house software. 
Resonance frequencies of 1HN, 15N in proteins can trace perturbations, and hence is 
used universally to analyse protein-protein interactions and to determine protein 
binding interface Differences between 1HN-15N NMR spectra were quantified as 
chemical shift perturbations (CSPs), defined as: CSP = [(dHA – dHB)2 + ((dNA – 
dNB)/5)2]1/2. Here dH and dN are chemical shifts of 1H and 15N, respectively, for a given 
backbone N-H group. Titration experiments monitoring chemical shift changes 
occurring upon 15N Ub binding to UbcH5B/UbcH6 was performed by sequential 
addition of unlabelled UbcH5B/UbcH6 to ~0.3mM 15N Ub. 1H-15N NMR recorded 
at each titration step monitored the binding.  
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Chapter 3 
 
Role of non-covalent ubiquitin in 
cIAP1- mediated ubiquitin transfer 
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3.1 Aims and Objectives   
There are several structures of RING E3s in complex with E2~Ub that show how 
RING E3s restrain E2~Ub in a closed conformation thereby making the E2~Ub 
thioester bond optimal for Ub transfer [40, 67, 68, 73, 146]. Structural and 
biochemical studies show that RING E3s stabilise donor Ub in a closed conformation 
together with E2, such that residues in E2’s active site clamp Ub’s C-terminal tail and 
position the thioester for nucleophilic attack.  These structures show that in addition 
to the RING domain, other factors also contribute to the increase the processivity of 
Ub transfer. Several RING E3s contain a domain or motif outside the RING domain 
that assists the RING domain in stabilising the closed donor Ub (UbD) conformation; 
examples include the phosphorylated tyrosine in the linker helix region (LHR) of Cbl 
proteins and the C-terminal tail of RING dimers such as BIRC7 and RNF4 [66, 67, 
73]. E2’s active site residues play an important role in creating an environment that 
favours catalysis; for example, the asparagine from the conserved His-Pro-Asn motif 
helps to stabilise the oxyanion intermediate in the transition state, and an aspartate on 
a loop near the active site cysteine reduces the pKa of the incoming substrate lysine 
[28, 29, 78, 147, 148]. Some RING E3s have an additional E2-binding motif that 
binds to the backside of E2s. In the case of the RING E3 gp78, its G2BR domain 
binds selectively to the E2 Ube2g2’s backside resulting in enhanced ubiquitylation 
[86]. Furthermore, Ub has been shown to bind the backside of some of E2s like 
UbcH5, UbcH6, Rad6 and Ube2g2 families and promote polyUb chain formation [36, 
87, 149, 150]. This non-covalent binding of Ub to the backside of UbcH5 family has 
been shown to increase the processivity of polyUb chain but the mechanism remains 
elusive [36, 38, 39].  
At the start of my PhD, our lab was investigating the mechanism by which non-
covalent Ub-binding to the backside of the UbcH5 family of E2s (this backside bound 
Ub is referred to as UbB) increases the processivity of polyUb formation. Our lab 
showed that UbB stimulates UbcH5B-catalyzed Ub transfer in both RING-dependent 
and RING-independent manners, but with a more prominent effect in RING-
dependent transfer. We showed that UbB enhances the affinity of RING E3s for 
UbcH5B~Ub [40]. In this study we used a monomeric RING E3, RNF38, for 
structural analyses and found that UbB stabilises UbcH5B’s  α1 and α1β1 loop 
conformations to enhance RING E3’s affinity for UbcH5B~Ub. To assess whether the 
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mechanism of UbB stimulation is conserved for other RING E3s, I have determined 
the structure of a dimeric RING E3, cIAP1, bound to UbcH5B–Ub and UbB. In this 
chapter, I will discuss how cIAP1 activates E2–Ub for transfer and how UbB 
influences cIAP1-UbcH5B–Ub complex to stimulate ubiquitination. I also present 
biochemical analyses to validate the structure and to characterise the UbB stimulatory 
effect.  
 
3.2 Results 
3.2.1 Purification of His-GST cIAP1 RING (cIAP1R) domain with 
TEV cleavage site 
 
The His-GST-TEV cIAP1 RING domain (cIAP1R; 556-616) construct was cloned by 
a former graduate student in the lab (Julia).  She did the first step of protein 
purification with Ni2+ pull down and stored the protein (approx. 100mgs in 35ml) at -
80° C. I performed the later steps of protein purification. First, I concentrated protein 
to 5 ml and then purified using 10 ml GSH sepharose beads on gravity column (see 
Methods Section 2.2.2). Eluted protein was then incubated with TEV overnight and 
dialysed against a buffer containing 50 mM Tris-HCl 7.6, 0.2 M NaCl and 1 mM 
DTT. Next day, the cleaved protein was passed back onto the GSH sepharose beads to 
remove His-GST-tag. Protein obtained after pass back was then purified using size 
exclusion chromatography (SD75 1660). Eluted protein was run on a SDS gel and 
marked bands were pooled (Figure 3-1), concentrated to 8.5 mg/ml, and stored at -80° 
C. 
 
Figure 3-1:  SD75/1660 elution profile of cIAP1R. Marked fractions were pooled 
and concentrated.  
~10 ~15 
~25 ~35 ~40 
~50 ~70 ~100 
~140 ~260 
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3.2.2 UbB enhances cIAP1’s affinity for UbcH5B~Ub 
Our lab has previously developed a method for measuring RING E3’s affinity for 
E2~Ub by using Surface Plasmon Resonance (SPR) analyses (see Methods). Briefly, 
GST-tag cIAP1R was captured on a CM5 chip that was coupled with anti-GST 
antibody and binding was measured for a range of UbcH5B–Ub concentrations. To 
assess the effect of UbB on RING E3’s affinity for UbcH5B–Ub, a fixed, saturated Ub 
concentration was included with all UbcH5B–Ub concentrations tested. My 
colleague, Gary Sibbet, performed all of the SPR experiments. We generated a stable 
UbcH5B–Ub complex by mutating UbcH5B’s catalytic cysteine (Cys85) to lysine, 
thereby forming a stable amide linkage that mimics the thioester linkage (hereafter 
UbcH5B C85K–Ub is referred to as UbcH5B–Ub; [73]. GST-cIAP1R exhibited ~85-
fold higher binding affinity for UbcH5B–Ub than UbcH5B. Addition of excess of Ub 
(0.6 mM; Kd for UbB-UbcH5B is ~300 µM; [40]) further enhanced GST-cIAP1R’s 
binding affinity for UbcH5B–Ub by ~10 fold (Table 3-1) (Figure 3-2). As a control 
we measured GST-cIAP1R’s binding affinity for UbcH5B S22R–Ub (the S22R 
substitution abrogates backside Ub binding; [36] and found that GST-cIAP1R 
displayed a similar affinity for UbcH5B S22R–Ub as for UbcH5B–Ub, but there was 
no improvement in binding upon adding excess Ub, suggesting that interaction 
between UbcH5B’s backside and free Ub is necessary for UbB to exert its stimulatory 
effect. These observations were consistent with our prior study with other RING/U-
box domains such as RNF38, UBE4B and BIRC4 [40]. Together my data showed that 
UbB enhances cIAP1R’s affinity for UbcH5B–Ub. 
 
Table: 3-1: Dissociation constants (Kd) for interactions between cIAP1R, 
UbcH5B, UbcH5B–Ub with and without excess Ub 
Ligand Analyte Kd (µM) 
GST-cIAP1R UbcH5B  223 ± 29 
GST-cIAP1R UbcH5B–Ub 2.7	±	0.7 
 
GST-cIAP1R UbcH5B–Ub + 0.6 mM Ub 0.49 ± 0.14 
GST-cIAP1R UbcH5B S22R–Ub 2.7	±	0.7 
 
GST-cIAP1R UbcH5B S22R–Ub + 0.6 mM Ub 2.7	±	0.6 
 
GST-Ub UbcH5B–Ub + cIAP1R  13 ± 2 
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Figure 3-2: SPR binding data showing representative sensograms (left) and 
binding curves (right). (A) Sensogram and binding curve for UbcH5B and GST-
cIAP1R. (B) Sensogram and binding curve for UbcH5B–Ub and GST-cIAP1R. (C) 
Sensogram and binding curve for UbcH5B–Ub + 0.6 mM Ub and GST-cIAP1R. (D) 
Sensogram and binding curve for UbcH5B S22R–Ub and GST-cIAP1R. (E) 
Sensogram and binding curve for UbcH5B S22R–Ub and GST-cIAP1R. (F) 
Sensogram and binding curve for GST-Ub and UbcH5B–Ub in the presence of 
cIAP1R. 
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3.2.3 UbB stimulates cIAP1R-catalysed Ub transfer 
To assess the effect of UbB on cIAP1R-catalysed Ub transfer, I performed in vitro 
single turnover UbcH5B~Ub discharge assays using wild-type (WT) UbcH5B (Figure 
3-3A) and UbcH5B S22R (Figure 3-3B). UbcH5B WT and S22R were precharged 
with equimolar concentrations of 32P-Ub and then chased by adding cIAP1R alone 
and in the presence of UbΔGG. UbΔGG lacks the C-terminal Gly-Gly motif and 
cannot be charged by E1, but can still bind to the backside of UbcH5B WT. Addition 
of UbΔGG stimulated discharge of UbcH5B~Ub but had no effect on UbcH5B 
S22R~Ub (Figure 3-3). Thus, UbB stimulates cIAP1R-catalysed Ub transfer. 
 
Figure 3-3: Lysine discharge assays of UbcH5B WT and S22R. (A) Non-reduced 
autoradiogram of lysine discharge assays of UbcH5B WT (B) Non-reduced 
autoradiogram of lysine discharge assays of UbcH5B S22R. Significant 
disappearance of UbcH5B~32P-Ub in presence of cIAP-1R and with and without 
excess Ub. 
 
3.2.4 Crystallisation of cIAP1R-UbcH5B–Ub-UbB complex 
The SPR analyses showed that cIAP1R binds UbcH5B–Ub with a Kd of ~0.4 µM in 
the presence of excess Ub. To obtain cIAP1R-UbcH5B–Ub-UbB complex, cIAP1R 
(8.5 mg/ml), UbcH5B–Ub (20 mg/ml) and Ub (100 mg/ml) were mixed at 1:1:1.2 
molar ratio such that final concentration of cIAP1R was ~5.5-6 mg/ml. I screened the 
complex in 1000 different crystallisation conditions. Crystals were obtained in 
conditions containing PEG3350 from the initial screen and subsequently optimised. 
To confirm if the crystals contained all components in the complex, crystals were 
washed and separated on an SDS gel (Figure 3-4B). The SDS gel showed that 
UbcH5B–Ub and an additional band that corresponds in size to both Ub and cIAP1R 
was present. Since both cIAP1R and Ub have a similar molecular weight, whether 
both components were present was unclear. Nonetheless, I collected data at Diamond 
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Light Source and determined the structure by molecular replacement (see Section 
2.6.2). I found that UbcH5B–Ub, cIAP1R and UbB were all present.
 
Figure 3-4: Crystallisation of cIAP1R-UbcH5B–Ub-UbB  complex. (A) Crystals of 
cIAP1R-UbcH5B–Ub-UbB complex. (B) SDS gel showing protein components in the 
protein crystals from (A). A mixture of complex (lane 1) was run as the control. Lane 
2 contains the components in the protein crystals. cIAP1R and Ub have a similar 
molecular weight of ~10 kDa. 
 
3.2.5   Structure of cIAP1R-UbcH5B–Ub-UbB complex 
The cIAP1R-UbcH5B–Ub-UbB complex crystals belong to space group C121 with 
one copy of cIAP1R-UbcH5B–Ub-UbB complex in the asymmetric unit. The structure 
was refined to a resolution of 1.7 Å (Table 3-2). Since cIAP1 exists as biological 
homodimer via the RING domain [136-138], I used crystallographic symmetry to 
generate a symmetry mate to form a dimeric cIAP1R-UbcH5B–Ub-UbB complex. 
(Figure 3-5). The structure shows that cIAP1R dimerises via the RING domain, the C-
terminal tail , and a helix that precedes the RING domain. This arrangement is similar 
to that observed in other IAP family RING E3s such as cIAP2, XIAP and BIRC7 [66, 
77, 151]. cIAP1R’s RING domain binds both UbcH5B and UbD and arranges 
UbcH5B–Ub complex in a closed conformation. Additionally, the C-terminal tail of 
the second subunit in the cIAP1R dimer also packs against UbD to stabilise the closed 
UbcH5B–Ub conformation. The closed UbcH5B–Ub conformation observed here is 
similar to that observed in other structures of RING E3-E2–Ub complexes [40, 66-68, 
73, 146]. In the structure, UbB binds to the backside of UbcH5B centring on the Ser22 
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surface as reported previously [36, 40]. In the following sections, I will explain how 
cIAP1R binds and activates UbcH5B–Ub and how UbB stimulates the activity. 
Table 3-2: Diffraction and refinement statistics cIAP1R-UbcH5B–Ub-UbB  
complex 
 
Data Collection 
Space group  C 1 2 1 
Cell dimensions  
a, b, c (Å) 79.19  53.60  78.54 
α,  β, γ (°)                                    90, 107.57, 90 
Resolution (Å)  23.67-1.70 
Rmerge    0.051 (0.029-0.474) 
I/σ  13.8    (41.3-2.0) 
Completeness (%)  98.8    (94.8-94.7)  
Redundancy 3.29 
Wilson B factor  47.18 
Refinement  
Resolution (Å)  (23.52-1.70)* 
No. Reflections                              34206 
Rfree/Rwork  0.23/0.20 
No. atoms  
   Protein 2777 
    Ions 2 
   Water                                            217 
R.m.s. deviations  
Bond length (Å)  0.007 
Bond angles (°)  1.20 
  
 
* values indicates highest-resolution shell 
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Figure 3-5: Crystal structure of cIAP1R-UbcH5B–Ub-UbB (A) cartoon 
representation of dimeric cIAP1R bound to UbcH5B–Ub and UbB. One subunit of 
cIAP1R is in pink and the other is in orange. UbcH5B is in light blue; UbD is in pale 
green; and UbB  is in wheat. Zn2+ ions are shown as grey spheres. UbcH5B–Ub 
linkage is highlighted in red. (B) 90° rotation of complex in A. cIAP1R subunits are 
coloured in orange and green, UbcH5B in light blue, UbD in yellow and UbB is 
coloured in wheat. 
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3.2.6 Interactions important for the closed E2–Ub conformation 
There are two key interactions that are crucial for the observed closed E2–Ub 
conformation in my structure: (I) the RING domain and C-terminal tail of cIAP1R 
with UbD and (II) UbcH5Band UbD interaction.  
(I) cIAP1R-UbD : The structure shows that the C-terminal tail of cIAP1R of one 
protomer packs against UbD that is bound to cIAP1R in the second protomer: Arg614 
and Phe616 from the C-terminal tail of one subunit pack against Ub’s Gly35 surface 
(Figure 3-6A). The interaction between a hydrophobic tail residue from the RING E3 
and UbD was observed in our prior structure of BIRC7-UbcH5B–Ub complex and in 
other complexes of dimeric RING E3s such as RNF4 and MDM2/MDM4 bound to 
E2–Ub [66, 67, 74]. In all cases, substitution of Phe or Tyr at this position on these 
RING E3s to a histidine or alanine disrupted the ligase activity. Previous studies have 
also shown that Phe616 also plays an important role in RING E3 dimerisation [66, 
77]. To determine the importance of this residue, I mutated cIAP1R’s Phe616 to His 
and performed lysine discharge assays to assess the effect on Ub transfer. I found that 
the F616H mutant was defective in discharging UbcH5B~Ub (Figure 3.6D), 
suggesting that this interaction is important in stabilising the closed UbcH5B–Ub 
conformation. Consistent with my finding, an earlier study showed that substitution of 
cIAP1’s Phe616 to His abrogated its activity [152]. 
In the RING domain of cIAP1R, Arg606 plays a crucial role by pinning UbD and 
UbcH5B together. It stabilises UbD by forming hydrogen bonds with Arg72 and 
Glu40 of UbD (Figure 3-6A). Direct interactions between Arg606 of cIAP1R and 
Arg72 of UbD constrains the C-terminal tail of ubiquitin in a conformation in which 
the thioester is more reactive (Figure 3-6B). This interaction has been previously 
observed in other RING-E2–Ub structures [48, 66, 76], and is consistent with 
Arg606’s assigned function as a linchpin that stabilises UbD for optimal transfer. To 
assess the important of it in my structure, I mutated Arg606 to Ala and performed 
lysine discharge assays. The mutant (R606A) was defective in UbcH5B~Ub transfer 
(Figure 3-6E)). Hence, the function of this Arg as a linchpin in RING-mediated Ub 
transfer is conserved in cIAP1R. 
Apart from cIAP1R’s Phe616 and Arg606, Ile36 of UbD interacts with cIAP1R’s C-
terminus and RING domain via hydrophobic and hydrophilic interactions (Figure 3-
6A). These interactions provide additional stability to RING-UbD interactions. These 
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interactions consist of Arg614 at the C-terminus of cIAP1R forming a hydrogen bond 
with Asp32 of UbD, and His588, Ileu604 and Cys592 from cIAP1R’s RING domain 
interacting with Leu8, Ileu36 and Pro37 of UbD. Again, to determine the role of Ile36 
in RING-mediated Ub transfer, I mutated Ile36 to Ala and performed lysine discharge 
assays to visualise its effects. Ub Ile36A does not charge complete [40, 66], to make 
the results comparable I charged WT Ub similar to Ub I36A. My results showed that 
the mutant is defective in UbcH5B~Ub discharge. (Figure 3-6F). 
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Figure 3-6: Interactions of cIAP-1R C-terminal tail. (A) Close-up cartoon 
representation of interactions between UbD and the RING domain and C-terminal tail 
of cIAP1R. Colouring is as described in Figure 3-5 Interacting residues are shown in 
stick with putative hydrogen bonds shown with dashes. (B) Non-reduced SDS gels of 
lysine discharge assays of cIAP1R WT, cIAP1R R606A and F616H. * indicates 
impurity. (C) Non-reduced SDS gels of lysine discharge assays of Ub WT and Ub 
I36A. * indicates impurity. (D) A representative SDS gel showing the effects of 
cIAP1R mutants in discharging  UbcH5B~Ub to L-lysine in presence of 300 µM Ub 
in 0.5 minutes. (E) A bar graph showing fraction of UbcH5B~Ub left in (D). (F) A 
representative SDS gel showing the effects of Ub mutant in discharging  UbcH5B~Ub 
to L-lysine in presence of 300 µM Ub in 0.5 minutes. (G) A bar graph showing 
fraction of UbcH5B~Ub left in (F). 
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(II) UbcH5B and UbD interactions: cIAP1R binds UbcH5B–Ub such that it restrains 
UbcH5B–Ub in a closed configuration. This closed UbcH5B–Ub interaction is further 
stabilised by interactions between UbD and UbcH5B. Ubiquitin’s Ileu44 patch 
interacts with the α3-helix of UbcH5B (Figure 3-7A). The interactions between 
UbcH5B and Ub are stabilised by hydrophobic interactions between Ser108 of 
UbcH5B and His68 and Val70 of Ub. These interactions were also previously 
observed in the complex structure of BIRC7 bound to UbcH5B~Ub (Dou et al. 2012). 
Additional interactions are also observed between Lys48, Gln49,and Arg42 of Ub and 
UbcH5B’s Asp112, Leu104,and Lys101 (Figure 3-7A).  
To investigate the importance of these interactions, I performed single-turnover lysine 
discharge assays using Ub in which Ile44 was substituted to Ala or UbcH5B in which 
Ser108 was substituted to Arg. In both cases, RING-mediated ubiquitin transfer was 
impaired (Figure 3-7B).  
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Figure 3-7: Interactions between UbD and UbcH5B (A) Close up of boxed region 
shown on left showing interactions between the Ile44 patch of UbD and UbcH5B. (B) 
Close up of interactions between UbcH5B’s α2-helix and the tail of Ub (C) Non-
reduced SDS gels of single turnover lysine discharge assays of UbcH5B WT, S108R 
and I88A. (D) Non-reduced SDS gels of single turnover lysine discharge assays of Ub 
WT, I44A and L73D. (E) A representative SDS gel showing the effects of UbcH5B 
mutants in discharging  UbcH5B~Ub to L-lysine in presence of 300 µM Ub in 0.5 
minutes. (F) A bar graph showing fraction of UbcH5B variant~Ub left in (E). (G) A 
representative SDS gel showing the effects of Ub mutants in discharging  
UbcH5B~Ub to L-lysine in presence of 300 µM Ub in 0.5 minutes. (H) A bar graph 
showing fraction of UbcH5B variant~Ub left in (G).  
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The C-terminal tail of Ub is extended and lies along the interface between UbcH5B’s 
helices(Figure 3-7B). As shown in the figure, hydrophobic interactions are formed 
between UbcH5B’s Ileu88 and Ub’s Leu73. Other interactions shown in figure are 
between backbone nitrogen of UbcH5B Asp87 and the backbone oxygen of Ub’s 
Arg74. To validate the effect of important residues between UbcH5B and Ub tail, I 
mutated Ub’s Leu73 to Asp (L73D) and performed lysine discharge assay with the 
mutant. Results showed that the mutant was defective in UbcH5B~Ub discharge. 
Similarly, I tested residue from UbcH5B’s α2, helix by mutating Ileu88 to Ala (I88A) 
and performed lysine discharge assays with it. The mutant was found to be defective 
in UbcH5B~Ub discharge (Figure 3-7C). It has been previously shown Ub mutants 
L73D and I44A does not charge complete [66]. 
 
3.2.7 Comparison between cIAP1 and cIAP2 to understand ubiquitin 
transfer 
The RING domains of cIAP1 and cIAP2 have conserved structures and sequences 
(Figure 3-8A,B). My structure is the only structure at present of either of these two 
RING domains bound to a Ub-conjugated E2. Mace et al.(2008) solved the first 
structure of dimeric cIAP2 RING alone and with UbcH5B and demonstrated that the 
RING domain undergoes structural changes on binding to E2. However, there was no 
structural information on the RING mediates ubiquitin transfer. Superposition of the 
structures of cIAP2 bound to UbcH5B with our cIAP1R bond to UbcH5B~Ub 
structure (r.m.s.d. of 0.914 Å) revealed that Arg606 in cIAP-1 is rotated by 7Å 
compared to the equivalent of Arg in cIAP-2 (Arg592, Figure 3-8C). This rotation of 
Arg606 enables the RING domain of cIAP-1 to interact with Arg72 and Gln40 of 
UbcH5B and UbD. This observation and the Ub-RING tail interactions discussed 
above provide additional insights into the mechanism of ubiquitin transfer in IAP 
RING E3 ligases. In the cIAP2R-UbcH5B structure, Arg592 forms hydrogen bond 
with UbcH5B’s Gln92. Furthermore there is a slight rotation in UbcH5B relative to 
the RING domain (Figure 3-8C). These differences show that the presence of UbD 
could influence how RING E3 interacts with E2. 
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Figure 3-8: Structural comparison of cIAP1R-UbcH5B–Ub and cIAP-2R-
UbcH5B (A) Sequence alignment of cIAP1R(556-C) domain with cIAP-2R domain 
(541-C) using MegAlign from DNAstar. Matched residues are shaded in yellow. (B) 
On left cIAP-1R(orange) superposed with cIAP-2R(green)(PDB ID: 3EB5). On right, 
cIAP-1R-UbcH5B (orange and light blue, respectively) superposed with cIAP-2R-
UbcH5B (PDB ID: 3EB6)(green and magenta, respectively) (c) On left, superposed 
UbcH5B from cIAP-1R(light blue) and cIAP-2R(magenta). On right, Arg606 from 
cIAP-1R (orange) superposed with Arg592 from cIAP-2R(green) to show interactions 
with Glu92 of UbcH5B in light blue. 
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3.2.8 UbB  as an allosteric activator of cIAP1 mediated Ub transfer  
UbB binds UbcH5B via the Ile44 hydrophobic patch on UbB and UbcH5B’s backside 
β1-3 surface around Ser22. This binding mode resembles other available structures of 
UbcH5 family E2s bound to UbB [36, 38, 40, 153]. In my structure, UbB does not 
contact cIAP1R or UbD. In addition to UbcH5B’s Ser22 surface, UbB also contacts 
UbcH5B’s α1β1 loop, which in turn packs against UbD (Figure 3-9A). Here, UbB‘s 
Lys6 and His68 form hydrogen bonds with carbonyl oxygens of UbcH5B’s Pro17 and 
Pro18, respectively, and Leu8 packs against UbcH5B’s Gln20 thereby placing Gln20 
within hydrogen bonding distance of the backbone amide of UbD’s Gly47 (Figure 3-
9B). To test the importance of Gln20, I used mutant UbcH5B Q20A (expressed and 
purified by Lori and Mads) to perform CIAP1R-mediated lysine discharge assays. 
The rate of UbcH5B Q20A~Ub discharge in the presence and absence of excess of 
Ub remained the same, suggesting that Gln20 plays an important role in UbB-
mediated stimulation of Ub transfer (Figure 3-9E). Our lab has previously determined 
the structures of a monomeric RING E3, RNF38, bound to UbcH5B–Ub alone and in 
complex with UbB [40]. When I compared the α1β1 loop in my structure to UbcH5B–
Ub-RNF38 (where there is no UbB), I observed that Gln20 is shifted in my structure 
(Figure 3-9C). This shift was also present in the comparison of UbB-UbcH5B–Ub-
RNF38 to UbcH5B–Ub-RNF38. Consistent with this earlier study, my structure 
showed that UbB packs against UbcH5B’s α1β1 loop to further stabilise UbD in the 
closed conformation (Figure 3-9D).   
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Figure 3-9: Mechanistic aspects of UbB-stimulation (A) Close-up view of UbB in 
wheat colour interacting with UbcH5B’s α1β1 loop coloured in light blue. Binding to 
the backside of UbcH5B occurs via the Ile44 hydrophobic patch of UbB. (B) close-up 
of interactions of residues from UbcH5B and UbB are shown in sticks. Putative 
hydrogen bonds are shown in dashed lines (C) Close-up view of UbcH5B’s α1β1 loop 
from the overlaid structures of RNF38-UbcH5B–Ub (PDB ID: 4V3K; UbcH5B is in 
green) and UbB-UbcH5B–Ub-cIAP1R(unpublished; UbcH5B is in light blue) 
complexes (D) Close-up view of UbcH5B’s α1β1 loop from the overlaid structures of 
UbB-UbcH5B–Ub-RNF38 (UbcH5B is in green and UbB in yellow) and UbB-
UbcH5B–Ub-cIAP1R (UbcH5B is in light blue and UbB is in wheat) complexes (E) 
Non-reducing SDS-PAGE showing the disappearance of UbcH5B WT and Q20A~Ub 
over time catalysed by cIAP1R in the presence and absence of excess Ub. (F) A 
representative SDS gel showing the effects of UbcH5B mutants in discharging  
UbcH5B~Ub to L-lysine in presence of 300 μM Ub in 0.5 minutes.(G) A bar graph 
showing fraction of UbcH5B variant ~Ub left in (F). 
 
There are several structures of UbB bound to E2. Superimposition of the existing UbB-
E2 structures from UbB-UbcH5C (PDB ID: 2FUH)[36] and UbB-UbcH5B–Ub-
RNF38 (PDB ID: 4V3L)[40] onto my structure by overlaying the E2 structures 
showed a slight rotation in the UbB conformation relative to the E2 (Figure 3-10C). In 
comparison with UbB-UbcH5C and UbB-UbcH5B–Ub-RNF38 structures, UbB in my 
structure has rotated by ~5° and 10°, respectively (Figure 3-10A,B). Despite these 
differences, UbB still makes contacts with UbcH5’s α1β1 loop in all three structures. 
Notably, the conformation of UbcH5’s α1β1 loop is identical in both UbB-UbcH5B–
Ub-RNF38 complex and UbB-UbcH5B–Ub-cIAP1R complex structures (Figure 3-
9D). In all other UbcH5B-containing structures, this loop adopts various 
conformations (Figure 3-9C). Thus, my results showed that irrespective of the 
oligomeric state of the RING E3, UbB functions to stabilise UbcH5’s α1β1 loop, 
which in turn packs against UbD to further stabilise the closed UbcH5B–Ub 
conformation to stimulate RING E3-catalysed Ub transfer.  
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Figure 3-10: Comparing UbB from cIAP1R-UbcH5B–Ub-UbB with RNF38-
UbcH5B–Ub-UbB (PDB ID: 4V3L) and UbcH5C-UbB (PDB ID: 2FUH) (A) 
Superimposition of UbB-UbcH5B portion of structure from cIAP1R-UbcH5B–Ub-
UbB complex (UbcH5B is in light blue and UbB is in wheat) onto UbB-UbcH5C 
complex (PDBID 2FUH; UbcH5C is magenta and UbB is cyan) by aligning the E2 
structures. Left and right panels show the overlaid UbB-E2 complex and UbB, 
respectively. A red arrow indicates UbB rotation. (B) Superimposition of UbB-
UbcH5B portion of structure from cIAP1R-UbcH5B–Ub-UbB complex (coloured as 
in A) onto UbB-UbcH5B portion of structure from RNF38-UbcH5B–Ub-UbB complex 
(PDB ID: 4V3L; UbcH5B is in green and UbB is in yellow) by aligning the E2 
structures. Left and right panels show the overlaid UbB-UbcH5B complex and UbB, 
respectively. A red arrow indicates UbB rotation. (C) Overlaid structures of UbB-E2 
portion of structures from RNF38 UbcH5B–Ub-UbB (PDB ID: 4V3L; coloured as in 
B) and cIAP1R-UbcH5B–Ub-UbB (coloured as in A) complexes and UbB-UbcH5C 
(PDB ID: 2FUH; coloured as in A). Left and right panels show the overlaid UbB-E2 
complexes and UbB, respectively. A red arrow indicates UbB rotation.  
 
3.2.9 UbB stimulating mechanism observed across UbcH5 family 
The UbcH5 family of E2s are evolutionarily conserved and widely expressed in 
humans [34]. This group of E2s consists of four genes known as UbcH5A, UbcH5B, 
UbcH5C and UbcH5D, amongst which the most commonly studied are UbcH5A-C.  
These human proteins have at least 88% sequence identity and 95% sequence 
similarity to each other (Figure 3-11A) [36]. Structures of UbcH5A–C reveal that 
their UBC domain is conserved and additional studies have shown similar 
functionality in vitro and in vivo (Figure 3-11B) [34].  
Although there is lot of structural and functional information available about the 
UbcH5A-C families, not much is known about UbcH5D. Studies on UbcH5A and 
UbcH5C show that the UbB-E2 interaction is important for processivity of polyUb 
chain formation as S22R substitution in both E2s reduced substrate ubiquitination [36, 
67]. To assess whether UbB also stimulates RING E3-catalysed Ub transfer with the 
UbcH5 family E2s, I performed single turnover Ub transfer assays. I precharged E2 
with Ub and then stopped and chased with cIAP1R and 20 mM lysine as the Ub 
acceptor in the presence and absence of 300 µM K0UbΔGG. Addition of 300 µM 
K0UbΔGG increased the rate of UbcH5~Ub discharge for all UbcH5 family E2s 
(Figure 3-11C). Thus, my results showed that UbB was able stimulate cIAP1R-
catalysed Ub transfer for the entire UbcH5 family of E2s.  
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Figure 3-11: UbB-stimulation is conserved across the UbcH5 family (A) Sequence 
alignment of UbcH5 family of E2s (UbcH5A–D) using clustalW method using 
MegAlign software. Strictly conserved residues are highlighted in yellow. (B) 
Cartoon representation of superimposed structures of UbcH5A (PDB ID: 2C4P; 
green), UbcH5B (PDB ID: 3TGD; cyan) and UbcH5C (PDB ID: 1X23; magenta). c) 
SDS-PAGE showing disappearance of UbcH5~Ub over time in lysine discharge 
reactions catalysed by cIAP1R in the absence (left) and presence (right) of K0UbΔGG 
for the UbcH5 family of E2s (indicated on the right). 
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3.3 Discussion 
The structure of cIAP1R-UbcH5B–Ub-UbB reported here is the first structure of a 
dimeric RING E3 bound to E2–Ub and UbB. Also this is the first structure of cIAP1 
bound to E2–Ub. The previous structure of cIAP2 bound to UbcH5B did not reveal 
the mechanism of Ub transfer as it lacked donor Ub [77]. However, a closely related 
IAP family E3, BIRC7, bound to UbcH5B–Ub provided insights into how the IAP 
family RING E3s activate E2~Ub complex for catalysis [66]. Consistent with these 
BIRC7 findings, I showed that cIAP1 activates Ub for transfer by restraining 
UbcH5B–Ub into the closed conformation that favours catalysis. This mechanism is 
also observed in several other RING E3-E2~Ub complexes. 
Similar to other RING E3-E2~Ub complexes, the closed E2~Ub conformation is 
stabilised by RING-E2, RING-UbD and UbD-E2 interactions. Crucially, a linchpin 
Arg (Arg606 in cIAP1) makes hydrogen bonds with carbonyl oxygens of Glu92 of 
UbcH5B and Arg72 of UbD and Gln40 side chain of UbD (Figure 3-5B). This 
interaction network is conserved in several structures of RING E3-E2~Ub complexes. 
I showed that substitution of this Arg in cIAP1 reduced ligase activity, consistent with 
earlier findings. Moreover, studies showed that Arg substitutions at this position 
influence the RING E3’s ability to populate E2~Ub in the closed conformation [66-
68, 76], highlighting the importance of this residue. 
In addition to the RING domain, cIAP1 contains a C-terminal tail that binds and 
stabilises UbD in a manner similar to that observed in the structures of BIRC7 and 
RNF4 bound to E2–Ub. My data showed that C-terminal tail of cIAP1 plays 
important roles in RING domain dimerisation and stabilisation of UbD in the closed 
conformation, thereby enhancing ligase activity (see section 3.2.5). The tail-UbD 
interaction occurs in trans, where the C-terminal tail of one of the RING domains 
from one subunit of the dimer binds UbD that is bound to the RING domain in the 
second subunit. This arrangement explains the importance of the RING domain 
dimerisation in regulating ligase activity. 
In 2006 Brzovic et al., showed that UbB binding to the backside of UbcH5C enhances 
the processivity of polyUb chain formation.  How UbB enhances polyUb chain 
formation was not well understood until our lab published a structure of RNF38-
UbcH5B–Ub-UbB and characterised its mechanism of action [40]. We showed that 
UbB improved RING E3’s affinity for UbcH5B~Ub and RING E3-UbcH5B~Ub 
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complex enhances UbB’s affinity for UbcH5B. This synergism results in the 
enhancement of the catalytic efficiency of RING E3-mediated Ub transfer, thereby 
enabling processive polyUb chain formation. We showed that UbB stimulates RING 
E3-UbcH5B~Ub complex by binding to UbcH5B’s α1β1 loop, which in turn pack 
against UbD to further stabilise UbD in the closed conformation.  
In the work described in this chapter, I wanted to understand whether this mechanism 
of UbB-stimulation is conserved for other RING E3s. Given that our previous 
structural work was performed with a monomeric RING E3, RNF38, I decided to 
investigate this mechanism using a dimeric RING E3, namely cIAP1. Comparison of 
the structures of cIAP1-UbcH5B–Ub-UbB with RNF38-UbcH5B–Ub-UbB  suggested 
that UbB stimulates Ub transfer in dimeric RING E3-mediated catalysis via a similar 
mechanism as observed earlier for monomeric RING E3s by Buetow et al. (2015) 
(Figure 3-9D). The α1β1 loop of UbcH5B makes extensive contacts with UbD in 
presence of UbB. Gln20 of UbcH5B interacts with backbone amide of Gly47 of UbD. 
In addition, Lys6 of UbB contacts the backbone carbonyl oxygen of Pro17 of 
UbcH5B, which was not evident in the structure of RNF38-UbcH5B–Ub-UbB 
complex. Despite the slight differences in how UbB interacts with UbcH5B’s α1β1 
loop and the orientation of UbB relative to UbcH5B, the conformation of UbcH5B’s 
α1β1 loop and its interaction with UbD are identical in both structures.  Thus my 
structure and data presented here further reinforced our proposed mechanism that UbB 
activates RING E3-UbcH5B–Ub complex by binding to UbcH5B’s α1β1 loop, which 
in turn stabilises the closed UbD conformation. 
Finally, I studied whether the mechanism of UbB stimulation is conserved in the 
UbcH5 family of E2s. The sequences of UbcH5 family E2s are highly conserved 
(section 3.2.11, Figure 3-11A). There is no crystal structure available for UbcH5D, 
but its sequence is similar to that of UbcH5B. To probe the UbB mechanism, I 
performed lysine discharge assays with UbcH5A, B, C and D. I found that UbB 
stimulates cIAP1R-mediated Ub transfer with all members of the UbcH5 family of 
E2s (Figure 3-11C). The α1β1 loop sequence of UbcH5A is different from other 
members of UbcH5 family. Gln20 is substituted with His in the α1β1 loop. It is 
unclear how His at this position influences interactions with UbD. Presumably the 
aromatic side chain of His could pack against UbD. Further studies are required to 
dissect how sequence variations in the α1β1 loop influence UbB stimulation. 
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Moreover, it is possible that there are other elements contributing to UbB-mediated 
stimulation that remains to be investigated. 
The SPR data showed that addition of excess Ub enhances cIAP1’s binding affinity 
for UbcH5B~Ub by ~10 fold. Likewise cIAP1R-UbcH5B–Ub complex enhances the 
binding affinity for UbB such the Kd is now ~13 μM (Table 3-1). This explains how a 
weak UbB-UbcH5B interaction (Kd of ~300 μM) could become relevant in cells where 
Ub concentration is between 20-85 μM. Collectively, this finding is consistent with 
our previous observation with the monomeric RING E3, RNF38 [40]. 
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Chapter 4 
 
 
Study of UbcH6’s backside 
binding mechanism 
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4.1 Aims and Objectives  
Several recent studies have shown the crucial role of interactions between E2 UBC 
domains and non-covalent ubiquitin in Ub transfer [36, 38, 40, 91]. These studies 
prompted me to investigate whether non-covalent Ub binding affects other E2s as 
well. To investigate this, I decided to study the core/UBC domain of UbcH6 (residues 
43-C). This E2 is also known as UbcH6 and hereafter this construct is referred to as 
UbcH6core. Previous work done by Schumacher and et al. in 2013 has shown that the 
UbcH5 and UbcH6 families of E2s both promote multi-mono and polyubiquitination 
of cIAP2. They also showed that non-covalent Ub does not interact with UbcH6, as 
substitution of a serine residue (Ser68; corresponding to UbcH5B’s Ser22) in the 
backside of UbcH6 did not hinder Ub transfer as observed in UbcH5 family E2s [43]. 
Since there is strong structural and sequence similarity between UbcH6 and UbcH5 
family E2s (see Section 1.5.3, Figure 1-8), I set out to investigate the relevance of 
UbB in regulating UbcH6-mediated Ub transfer. 
To investigate the UbcH6 backside mechanism, I performed ubiquitination and lysine 
discharge assays on UbcH6 WT and S68R using cIAP1. The cIAP1 construct used in 
these assays comprises the BIR3 (baculovirus inhibitor of apoptosis repeat 3), 
ubiquitin-associated (UBA), CARD and RING domains (residues 260-C; hereafter 
referred to as cIAP1(B3-C). I selected this construct because it is equivalent to the 
construct of cIAP2 used by [41] to investigate the effect of UbB on UbcH6. In this 
chapter, I show that UbcH6 has a weak binding affinity for UbB and UbB stimulation 
can only be achieved by adding at least 1 mM of free Ub. However, when cIAP1 is 
modified with polyUb chains, the Ub moieties from the polyUb chains can function as 
UbB in cis to overcome the high Ub concentration requirement to stimulate cIAP1-
catalysed UbcH6-mediated Ub transfer. Collectively my results showed that UbcH6 
relies on ubiquitin molecules from E3s or substrate modified with polyUb chains to 
serve as the source of UbB. E3-bound polyUb can greatly increase the local 
concentration of Ub to compensate for the weak backside Ub-binding affinity. Thus, 
UbcH6 utilises a distinct UbB-stimulation mechanism that is somewhat different to the 
UbcH5 family of E2s. 
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4.2 Results 
4.2.1 Purification of UbcH6core wild-type (WT) and S68R 
UbcH6core WT and S68R mutant were cloned in pRSFDuet vector containing an N-
terminal His-tag followed by a TEV cleavage site. Protein purification method for 
both the proteins was same. Below I have shown method for purifying UbcH6core WT. 
His-tagged UbcH6core WT was purified using 30 mL Ni2+ beads on a gravity column. 
Protein was eluted (for buffers used see Section 2.2.2) and run on a SDS gel to check 
for purity (Figure 4-1A). Fractions were pooled together and dialysed against buffer 
containing 50 mM Tris-HCl 7.6, 0.2 M NaCl and 5 mM β-mercaptoethanol with TEV 
(see section 2.5.1) overnight at 4 °C. The next day, the completeness of the TEV 
cleavage was assessed on an SDS gel (Figure 4-1B). The cleaved protein was passed 
back onto Ni2+ beads to remove any uncleaved protein. The cleaved protein was 
collected in the flow through and assessed by SDS-PAGE (Figure 4-1C). 
Subsequently protein was purified using cation exchange chromatography. Protein 
from Ni2+ pass back was diluted with buffer containing 50 mM MES 6.5 and 1 mM 
DTT to bring down the pH of the protein solution. The diluted protein was then 
loaded onto a 20 mL Source S column (buffers see section 2.2.2). A representative 
chromatogram for the elution from a Source S column is shown in Figure 4-1D. Peak 
fractions containing the protein were pooled and concentrated using Amicon ultra 
centrifugal filters. During concentration, protein was buffer exchanged to a buffer 
containing 50 mM Tris 7.6, 0.2 M NaCl and 1 mM DTT as UbcH6core is less stable in 
low NaCl and pH conditions (UbcH6core was eluted at 50 mM NaCl). After 
concentration, protein was loaded onto a gel filtration column (S75 10/300) (Figure 4-
1E). Peak fractions were analysed by SDS-PAGE (Figure 4-1F). All fractions shown 
in Figure 4-1F were pooled, aliquoted, snap frozen in liquid nitrogen and stored at    
-80 °C.  
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Figure 4-1: Purification of UbcH6core WT (A) SDS gel after Ni2+ pull down of 
UbcH6core. (B) SDS gel showing UbcH6core before and after TEV cleavage. (C) SDS 
gel showing UbcH6core after Ni2+-agarose pass back. (D) Chromatogram showing the 
elution profile of UbcH6core from a 20 mL Source S column. The biggest peak 
fraction contains UbcH6core. (E) SD75 gel filtration chromatography elution profile. 
The peak fraction contains UbcH6core. (F) SDS gel showing fractions eluted from the 
peak shown in (E). 
 
4.2.2 Non-covalent Ub binds to UbcH6core weakly 
To analyse the binding between Ub and UbcH6core, my lab colleague, Mark 
Nakasone, performed NMR experiments with 15N-labelled Ub and UbcH6core WT. 
Here, we titrated different concentrations of UbcH6core (from ~0.3 mM to ~2 mM) 
against 15N-labelled Ub (~0.305 mM). As a control, we titrated UbcH5B WT to 15N-
labelled Ub. We used NMR chemical shift perturbation (CSP) mapping to record 
signals of UbcH5B and UbcH6core bound to Ub. In Figure 4-2, I have shown CSP 
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plots for UbcH5B bound to 15N-labelled Ub (Figure 4-2A) and UbcH6core bound to 
15N-labelled Ub (Figure 4-2B). The CSP plots (Figure 4-2A and B) show signals 
indicating interactions with Ub for both E2s. Despite weak CSP signals for UbcH6core 
(Figure 4-2B) as compared to that of UbcH5B (Figure 4-2A), the Ub residues that 
undergo CSPs upon binding to UbcH5B and UbcH6core were similar. Figures 4-2B 
and 4-3 show that Ub’s Thr7, Ile13, ALa46, Lys48 and Leu71 undergo significant 
CSPs upon binding to UbcH6core.  
 
 
Figure 4-2: Chemical perturbation shifts (CSP) plots of Ub bound to UbcH5B 
and UbcH6core. (A) CSP plot in blue to show signals observed when 15N-labelled Ub 
binds to UbcH5B. On x-axis is the Ub residue number and y-axis indicates chemical 
shift perturbation. (B) CSP plot in red to show signals observed on 15N-labelled Ub 
binding to UbcH6core. On x-axis is the Ub residue number and y-axis indicates 
chemical shift perturbation 
 
Previous studies showed that the binding affinity between UbcH5 family E2s and Ub 
is between 200-300 µM [36, 40]. To measure the binding affinity between UbcH6core 
and Ub, we titrated UbcH6core to 15N-labelled Ub. Unfortunately, we could not 
saturate the binding even at 2 mM UbcH6core, indicating a very weak interaction. 
Together, these results suggest that UbcH6core contain a weak non-covalent binding 
surface for Ub and the interaction likely occurs via UbcH6core’s backside surface. 
A B 
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Figure 4-3: Chemical shift perturbation data for UbcH6core interactions with Ub. 
(A) 1H-15N HSQC spectra for 15N-labelled Ub alone (black) and titrated with 
increasing concentrations of UbcH6core (0.3 mM is in blue, 1 mM is in pink and 2 mM 
is in red). (B) Lys 48 of labelled Ub overlaid with five different points of 
concentration shown in different colour, with red be the highest concentration. (B) 
Chemical shifts shown for Lys 48, Lue71. 
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Since, peaks obtained from UbcH5B and UbcH6 were from similar residues, I 
mapped CSPs from 15N-Ub-UbcH6 spectra on Ub (Figure 4-4A) and UbB-UbcH5B 
from UbB-UbcH5B–Ub-cIAP1 structure (unpublished, chapter 3)(Figure 4-4B). From 
the figure it is evident that the mapped residues are interacting with UbcH5B’s 
backside. Therefore, it seems likely that Ub residues undergoing CSP when 
interacting with UbcH6 is due to non-covalent binding to UbcH6’s backside. 
 
 
 
Figure 4-4: CSPs mapped on Ub’s surface. (A) CSPs from figure 4-2 mapped onto 
Ub’s surface in red. (B) Mapped CSPs on UbB-UbcH5B structure from UbB-
UbcH5B–Ub-cIAP1 structure (unpublished, Chapter 3). UbB is coloured in wheat, 
UbcH5B in light blue. 
 
4.2.3. SPR analysis also showed weak UbcH6-Ub binding 
Since NMR did not give me exact Kd for UbcH6-Ub binding, I went on and 
performed SPR experiment to measure the binding affinity. I captured GST-tag Ub on 
a CM5 chip that was coupled with anti-GST antibody and binding was measured for 
range of UbcH6 concentrations, with 1mM as the highest and 0.2 µM as the lowest 
concentration. Sensogram and binding curve is shown in below Figure 4-5. 
Unfortunately, even at 1mM concentration, I could not saturate UbcH6 and hence did 
not get proper binding curve. Therefore, comparable with my NMR results, the 
binding affinity between UbcH6 and Ub is expected to be greater than 1mM.  
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Figure 4-5: SPR binding data showing representative sensograms. (A) Sensogram 
for UbcH6 and GST Ub. (B) Binding curve for UbcH6 and GST Ub. 
 
4.2.4   Stimulation by UbB of RING-catalysed UbcH6-mediated Ub 
transfer occurs at high Ub concentrations  
 
Previous studies showed that UbcH6core S68R had no effect on cIAP2 
autoubiquitination as compared with UbcH6core WT[41] whereas the corresponding 
S22R substitution in the UbcH5 family of E2s hindered RING E3-catalysed 
polyubiquitination [36, 38, 40, 91]. It is noteworthy that Schumacher et al., in 2013 
performed autoubiquitination assays in the presence of 50 µM of Ub. My NMR and 
SPR results showed that the Kd for the UbB-UbcH6 interaction is likely greater 
than   1 mM. Thus, it seems likely that higher Ub concentrations may be required to 
observe the effect of UbB in UbcH6-mediated Ub transfer. To assess whether Ub can 
stimulate UbcH6-mediated reactions, I performed lysine discharge assays in the 
presence of varying UbΔGG (deleted Gly-Gly motif at the C terminus of Ub, so that it 
cannot be charged by E1) concentrations. Detailed methodology for lysine discharge 
assay is shown in Methods section (See section 2.7). Briefly, I precharged both 
UbcH6core WT and S68R with 32P-Ub and then chased with a cocktail containing 
cIAP1(B3-C), lysine and varying concentrations of UbΔGG. Samples were removed 
to monitor the disappearance of UbcH6core~32P-Ub bands over time. Figure 4-6 shows 
that the rates of the disappearance of UbcH6core WT~Ub band were similar in the 
presence of 0, 20 and 300 µM Ub. However, in the presence of 1 mM UbΔGG, 
UbcH6core WT~Ub band disappeared faster than in the absence of UbΔGG indicating 
Ub-mediated stimulation (Figure 4-6). Moreover, incorporation of an S68R 
substitution in UbcH6 abrogated Ub-mediated stimulation, suggesting UbcH6’s 
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backside interaction with Ub is important for enhanced activity. Together my results 
showed that UbB stimulates cIAP1-UbcH6-catalysed reactions provided that excess 
Ub concentrations are high enough to at least partially saturate UbcH6’s backside. 
                        
 
Figure 4-6: Lysine discharge of UbcH6 WT and S68R with and without UbΔGG 
at indicated concentrations  
 
4.2.5 Assessing the effects of UbB on cIAP1-UbcH6-catalysed 
autoubiquitination  
 
Schumacher et al., in 2013 showed that, UbcH6core S68R had no effect on cIAP2 
autoubiquitination as compared with UbcH6core WT. In their assay, they only used 50 
µM Ub. Low Ub concentrations might explain their observation since I only saw UbB-
stimulation at 1 mM Ub. To further investigate these activity differences, I performed 
an autoubiquitination assay under similar conditions but for using cIAP1(B3-C) and 
Arabidopsis Uba1. cIAP1(B3-C) is comparable to the cIAP2 construct that was used 
by [41]. My reaction conditions were similar to those in the Frances-Rose study 
(2013), but I used a higher E1 concentration to ensure that UbcH6core is constantly 
recharged with Ub during the reaction and precharged the E2 prior to adding E3. In 
contrast to the aforementioned study, I found that UbcH6core WT catalysed cIAP1 
autoubiquitination faster than UbcH6core S68R (Figure 4-7A and B; see Section 2.11 
for detailed method of autoubiquitination assay). Since the total concentration of Ub 
in cells is in the low µM range [154, 155], I also performed autoubiquitination assay 
with 10 µM 32P-Ub (Figure 4-7A). Even at low Ub concentrations, autoubiquitination 
of  cIAP1(B3-C) is faster with UbcH6core WT than UbcH6core S68R. I further went 
ahead and quantified the gel. I performed three (n=3) independent autoubiquitination 
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assays of cIAP1 with UbcH6 WT and S68R under same conditions as mentioned 
above with 10 µM Ub. Results from quantification were analysed on Image lab from 
Biorad. (Figure 4-7C and D). The error bars in Figure 4-7D indicate standard 
deviation. 
In cells, substrate binding helps to stabilise some E3s by preventing their 
autoubiquitination and degradation [40, 156]. Since mature SMAC is the substrate for 
IAPs, I next examined how UbB-binding on UbcH6 affects cIAP1(B3-C)-mediated 
ubiquitination of mature SMAC (Figure 4-7C). The reactions were performed 
similarly to cIAP1 autoubiquitination where UbcH6core WT and S68R were 
precharged with 32P-Ub and then cIAP1 (B3-C) and 5 µM matured SMAC were 
added. Figure 4-7C shows that SMAC ubiquitination was faster in the presence of 
UbcH6core WT than UbcH6core S68R.  
It is unclear why Frances-Rose et al. did not observe the backside effect for UbcH6. It 
is speculative that the E1 concentration that they used was too low and hence it was 
not sufficient to recharge UbcH6 fast enough, thereby causing the E1-E2 reaction to 
become the rate-limiting step. We found that UbcH6 charging was not as efficient as 
UbcH5B charging. In my assays, it was surprising that 10 µM Ub was sufficient to 
observe UbB-stimulation in the autoubiquitination assays but not the lysine discharge 
assays. In the latter, I only observed UbB stimulation when an excess of 1 mM Ub was 
present. The major difference between the two assays is that in the autoubiquitination 
assays, cIAP1(B3-C) is modified with polyUb, whereas in the lysine discharge assay, 
Ub is discharged to lysine and hence cIAP1(B3-C) is not modified. This raises the 
question whether polyUb modified on cIAP1(B3-C) can function as the source of 
UbB. If so, this would enable polyUb to reach UbcH6’s backside in a cis arrangement 
thereby greatly increasing the local Ub concentration and overcoming the high Ub 
concentration requirement. 
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Figure 4-7: Ubiquitination assays for UbcH6core WT and S68R. (A) 
Autoradiogram showing cIAP1(B3-C) autoubiquitination in presence of UbcH6core 
WT and UbcH6core S68R over the time with 10 µM 32P-Ub. (B) Autoradiogram of 
cIAP1(B3-C) autoubiquitination in presence of UbcH6core WT and UbcH6core S68R 
over the time with 50 µM 32P-Ub. (C) A representative non-reduced SDS-PAGE gel 
showing effects of UbcH6 mutantions in cIAP1 autoubiquitination at the end of 10 
mins. (D) A bar graph showing fraction of cIAP1 left in (C). (E) Autoradiogram of 
cIAP1(B3-C)-mediated ubiquitination of mature SMAC with UbcH6core WT or 
UbcH6core S68R over time with 50 µM 32P-Ub. 
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4.2.6 Ubiquitinated cIAP1 acts as the source of UbB  
Our lab has previously shown that polyUb modified-BIRC4 can serve as a source of 
UbB to stimulate UbcH5B-catalysed Ub transfer [40, 92]. To determine whether 
polyUb modified-cIAP1(B3-C) can function as a source of UbB to stimulate UbcH6-
catalysed Ub transfer, I performed lysine discharge assays using UbcH6core WT and 
S68R with autoubiquitinated cIAP1(B3-C). I generated polyUb-cIAP1(B3-C) by 
incubating cIAP1(B3-C) with E1, Mg2+-ATP, UbcH5B and Ub and stopped the 
reaction by adding EDTA and apyrase. For control reactions, E1 was omitted. In a 
separate reaction, I charged UbcH6core WT or S68R with 32P-Ub and stopped charging 
after 15 minutes by adding apyrase and EDTA. I then added polyUb-cIAP1(B3-C) or 
control (described above) to the precharged reactions of UbcH6core WT~32P-Ub or 
UbcH6core S68R~32P-Ub and monitored the disappearance UbcH6core~32P-Ub band. 
Similar rates of discharge were observed for UbcH6core WT and S68R with the control 
cIAP1(B3-C) mixture, whereas the polyUb-cIAP1(B3-C) mixture stimulated the 
discharge of UbcH6core WT~32P-Ub but had no effect on the discharge of UbcH6core 
S68R~32P-Ub as compared to the control (Figure 4-8). Together these results 
demonstrate that covalently attached Ub molecules on cIAP1 function as a source of 
UbB to stimulate UbcH6-catalysed Ub transfer. 
 
 
 
Figure 4-8: Non-reduced autoradiogram showing disappearance of UbcH6core 
WT~32P-Ub (A) Lysine discharge assays showing the disappearance of UbcH6core 
WT~32P-Ub catalysed by control (-E1, left) and polyUb-cIAP1 (B3-C) (+E1, right). 
(B) Lysine discharge assays showing the disappearance of UbcH6core S68R~32P-Ub 
catalysed by control (-E1, left) and polyUb-cIAP1(B3-C) (+E1, right). 
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4.2.7 Ubiquitination of cIAP2 with UbcH6core WT and S68R 
I was curious to find out why I see a difference between UbcH6core WT and S68R 
with cIAP1 while Frances-Rose Schumacher et al., observed no difference between 
the two in their study with cIAP2. To further explore this difference, I decided to 
perform auotubiquitination assays with cIAP2 with UbcH6core WT and S68R. I 
generated the same fragment of cIAP2 (residues 255-C) that was used by Frances-
Rose Schumacher et al. in their study. My assay conditions were exactly the same as 
mentioned in section 4.2.5 and I again performed autoubiquitination assays with low 
(10 µM) and high (50 µM) 32P-Ub concentrations (Figure 4-9A and B respectively). I 
further went ahead and quantified the gel. I performed three (n=3) independent 
auotubiquination assays of cIAP2 with UbcH6 WT and S68R under same conditions 
as mentioned above with 10 µM Ub. Results from quantification were analysed on 
Imagelab from Biorad. (Figure 4-9C and D). The error bars in Figure 4-9D indicate 
standard deviation. Consistent with my cIAP1 results presented in Section 4.2.5, I 
found that cIAP2 catalysed autoubiquitination faster with UbcH6core WT than 
UbcH6core S68R, regardless of whether the Ub concentration was high or low. Thus, it 
seems likely that the E1 concentration used in the study by Frances-Rose Schumacher 
et al. was too low to keep UbcH6 constantly charged with Ub, thereby causing the E1-
E2 reaction to become the rate-limiting step. 
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Figure 4-9: Autoubiquitination assays of cIAP-2 for UbcH6 WT and S68R .  (A) 
Autoradiogram of pulsed-chased assay showing cIAP-2 autoubiquitination with 
UbcH6 WT and UbcH6 S68R over time with 10 µM 32P-Ub. (B) Autoradiogram of 
pulsed chased assay showing cIAP-2 autoubiquitination with UbcH6 WT and UbcH6 
S68R over time with 50 µM 32P-Ub. (C) A representative non-reduced SDS-PAGE 
gel showing effects of UbcH6 mutantions in cIAP2 autoubiquitination at the end of 10 
mins. (D) A bar graph showing fraction of cIAP2 left in (C). 
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4.3 Discussion 
At the beginning of the project, I was interested in understanding why UbcH6 lacks 
backside binding and stimulation as reported previously [41] despite sharing sequence 
and structural homology with the UbcH5 family of E2s (Section 1.5.3, Figure 1-8). To 
study this, I used the core domain of UbcH6 (the same construct that was previously 
used by Frances-Rose Schumacher et al.,) to investigate the role of UbcH6-backside 
binding of Ub. In 2015, our lab showed that non-covalent binding of Ub to the 
backside of UbcH5B enhances RING E3’s affinity for UbcH5B~Ub and the overall 
catalytic efficiency of the RING E3-UbcH5B~Ub complex to facilitate Ub transfer. 
Initially I examined whether I could observe binding between the backside of 
UbcH6core and non-covalent Ub. First I performed NMR experiments using 15N-
labelled Ub and found that addition of UbcH6core WT caused CSPs in Ub, suggesting 
binding between Ub and UbcH6. Furthermore these CSPs were similar to CSPs 
observed when UbcH5B was added to 15N-labelled Ub, suggesting the same surface 
on Ub is involved in binding both UbcH6 and UbcH5B. When these CSPs were 
mapped onto Ub, I found that this surface is involved in non-covalent Ub interaction 
with UbcH5’s backside. Thus, my data suggest that UbcH6 harbours a backside Ub-
binding property. However, the backside Ub binding affinity is very weak. The 
estimated Kd is likely greater than 1 mM since I only observed binding on SPR when 
1 mM Ub was added to UbcH6 and at 2 mM UbcH6core was insufficient to saturate 
15N-labelled Ub in NMR experiments. 
Given that UbcH6 harbours a UbB binding site, I then explored whether UbB could 
stimulate UbcH6-catalysed Ub transfer similar to that observed in the UbcH5 family 
of E2s (see Section 4.3; [36, 40]). First I performed lysine discharge assays and found 
that addition of 1 mM of Ub was necessary to stimulate cIAP1-UbcH6-catalysed Ub 
transfer. This process is initiated via UbcH6’s backside, as S68R substitution was 
unable to support stimulation. These data are consistent with the weak Ub-UbcH6 
interactions observed in SPR and NMR analyses. However, my data contradicted a 
previous finding [41], where there were no observable differences between UbcH6core 
WT and S68R in cIAP2-catalysed autoubiquitination assay. I performed similar 
reactions as described in this previous study using cIAP1 and cIAP2. In contrast to 
these previous findings [43], I found that both cIAP1 and cIAP2 catalysed 
autoubiquitination faster in the presence of UbcH6core WT than UbcH6core S68R. My 
reaction conditions were nearly identical to that reported previously [41] except I used 
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a higher E1 concentration and I precharged UbcH6 with Ub prior adding E3. Frances-
Rose et al. used only 10 nM E1 and did not precharge UbcH6 with Ub. I used a high 
E1 concentration and precharged UbcH6 with Ub to ensure that UbcH6 is constantly 
charged with Ub throughout the reaction cycle so that the E2-E3 reaction is the rate-
limiting step and not the E1-E2 reaction. It seems likely that in their reaction, the E1-
E2 reaction is rate-limiting. Hence they did not observe differences because the E1-
UbcH6core WT and E1-UbcH6core S68R transthiolation reactions probably occur at the 
same rate. 
One surprising observation is that in my autoubiquitination assays, 10 µM Ub was 
sufficient to enable UbB-stimulation whereas in the lysine discharge assay, 1 mM Ub 
was required to stimulate Ub transfer. The major difference between the two assays is 
the generation of polyUb-cIAP1 during the autoubiquitination reaction. To assess 
whether a Ub molecule from polyUb-modified cIAP1 could serve as the source of 
UbB for UbcH6, I generated polyUb-cIAP1 and used that in lysine discharge assays. I 
found the polyUb-cIAP1 readily stimulated the discharge of UbcH6core WT~Ub but 
not the S68R counterpart. It is noteworthy that with lysine discharge assay, I only 
observed stimulation in the presence of 1 mM Ub but now in the absence of 1 mM 
Ub, polyUb-cIAP1 readily stimulated the discharge.  
Collectively my results show that UbcH6 harbours a weak backside Ub-binding 
affinity. Cellular Ub concentrations are ~20-85 µM and therefore UbcH6 is unlikely 
to use free Ub as the source of UbB. Our lab previously showed that RING E3 binding 
could lower the Kd for UbcH5B~Ub’s affinity for UbB (from ~300 to 17 µM; [40]). I 
do not know whether RING E3 binding to UbcH6 could low UbB binding affinity. 
Given that at 300 µM Ub, there was no observable stimulation in lysine discharge 
assays, I speculate that the Kd for UbB-UbcH6 would remain quite high even in the 
presence of RING E3. Thus it is unlikely that UbcH6 could use free Ub as the source 
of UbB. However, once E3 is decorated with Ub via autoubiquitination, the ubiquitin 
molecules attached to the E3 can serve as a source of UbB (see Section 4.2.6). This 
would greatly increase the effective concentration of Ub owing to the cis 
arrangement, thereby overcoming the weak UbcH6-backside Ub binding affinity. This 
mechanism is somewhat different to UbcH5 family E2s, where these E2s can also 
utilise free Ub as the source of UbB. 
Together with all the above discussions, it is clear that in spite of weak binding 
between Ub and UbcH6, UbcH6 still retains its backside binding ability. A previous 
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study by our group suggests that UbB stabilises RING-E2~Ub complex by modulating 
the flexibility of E2’s α1β1 loop. [40] This mechanism of backside stimulation via the 
α1β1 loop was also observed in my UbB-UbcH5B–Ub-cIAP1 structure (see chapter 
3). UbcH6’s UBC domain resembles the UBC domains of UbcH5 family E2s, but its 
α1β1 loop contains an Asn substitution in place of the UbcH5 Gln that mediates UbB 
interactions with UbD. Initially, I believed this could be the reason for UbcH6’s weak 
binding, so I substituted UbcH6’s α1β1 Asn with Gln and but observed no differences 
in Ub transfer in lysine discharge or autoubiquitination assays. These data suggest that 
there is more to the mechanism of UbB-stimulation than stabilising the α1β1 loop of 
E2. It will require more structural, biophysical and biochemical understanding to 
elucidate UbB’s mechanism for stimulating RING-catalysed Ub transfer. 
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Chapter 5 
 
 
Study of RING mediated 
substrate poly- ubiquitination 
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5.1 Aims and Objectives 
How RING E3s coordinate Ub transfer from E2~Ub to a particular substrate lysine 
residue and subsequently promote Ub chain elongation are poorly understood. To 
investigate the latter step of the reaction, we sought to develop a model system for 
crystallisation trials that contains an E3 bound to E2~Ub and a monoubiquitinated 
substrate. Since numerous Cbl structures have been determined previously and several 
Cbl substrates are well-characterised, this ubiquitin ligase system was selected [62, 
73, 85]. 
In 2000, Zheng et al. solved the first structure of c-Cbl in complex with UbcH7 and 
ZAP70 peptide, where E2’s catalytic cysteine faces away from substrate and is ~70 Å 
from the substrate-binding site. This raised the question of how substrate 
ubiquitination occurs (Figure 5-1A) [62]. Subsequently our lab showed that 
phosphorylation of Tyr371 in c-Cbl activates its ligase activity by inducing 
conformational changes that enable juxtaposition of E2’s catalytic cysteine and the 
substrate binding site [85] (Figure 5-1B). Furthermore, our lab has determined a 
crystal structure of Tyr363 phosphorylated Cbl-b bound to E2–Ub and a ZAP70 
peptide [73] (Figure 5-1C).  
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 Figure 5-1: Structures of Cbl with E2 and ZAP70 peptide. Cbl is coloured in 
orange, LHR in pink, UbcH5B and UbcH7 is in light blue, ZAP70 peptide in 
cyan, catalytic Cys is shown in red sphere and Zn2+ ions in grey spheres. (A) 
Structure of c-Cbl-UbcH7-ZAP70 (PDB ID: 1FBV) (B) Structure of pc-Cbl-UbcH5B-
ZAP70 (PDB ID: 4A4C) (C) Structure of pCbl-b-UbcH5B–Ub-ZAP70 (PDB ID: 
3ZNI)[73]. The distance between E2’s catalytic cysteine and ZAP70 peptide is ~27Å. 
ZAP70 peptide does not have any lysines.  
 
 
In this structure, E2–Ub faces ZAP70 peptide in an arrangement similar to that 
observed in the structure of pTyr371-c-Cbl-E2-ZAP70 peptide complex (Figure 5-
1B). In the aforementioned complex structures, no lysine residues are present in 
ZAP70 peptide. Given the proximity of ZAP70 peptide to the E2–Ub thioester bond, 
we reasoned that generation of a Ub fused to ZAP70 (referred to as Ub-ZAP70 from 
now onwards) peptide or other Cbl substrate peptides might function as a 
“ubiquitinated substrate” mimetic. Since it is difficult to generate a site-specific 
monoubiquitinated substrate to study Ub chain elongation process, in this chapter I 
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discuss my development of a Ub-fusion strategy to study Cbl-mediated Ub chain 
elongation. A model demonstrating the objective of this chapter is shown in Figure 5-
2.  
 
                        
Figure 5-2: Schematic of  Ub-ZAP70 peptide in pCbl-b-UbcH5B–Ub ZAP70 
structure (PDB ID: 3ZNI) [73]. In this figure, Ub’s C-terminus is attached to a 
linker, which in turn is attached to the N-terminus of ZAP70 peptide. The model 
suggests that several Ub lysine residues are in close proximity to E2’s catalytic 
Cys85. 
 
In the above figure, Ub is fused via its C-terminal tail to a linker that is followed by 
ZAP70 peptide. The model suggests that Ub can fill the gap between E2’s active site 
and the substrate-binding site. In the model, my substrate mimetic, Ub-linker-ZAP70, 
has several lysine sites that potentially sit in close proximity to E2’s active site 
(Figure 5-1C).  
5.2 Results 
5.2.1 Generation of Ub fused to Cbl substrate peptide (Ub-peptide) 
To generate a monoubiquitinated substrate mimetic, I fused Ub to the N-terminus of 
several Cbl substrate peptides. Given the proximity of ZAP70 peptide and the E2~Ub 
thioester bond in the crystal structure (Figure 5-1C), we hypothesised that each Ub 
moiety in our Ub-fused Cbl substrate peptides would be sufficiently proximal to the 
E2~Ub thioester bond to function as an acceptor. Using this strategy, I fused Ub to the 
N-terminus of ZAP70, Src, EGFR and c-MET peptides (Table 5-1). These peptides 
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have been shown to bind c-Cbl and Cbl-b’s substrate-binding domain upon tyrosine 
phosphorylation [105, 121, 157]. Initially, my supervisor Danny Huang designed 
several constructs in which three Gly-Gly-Ser linkers were used to fuse Ub to the N-
terminus of these peptides as illustrated in Figure 5-3A. 
 
Table 5-1: Protein sequences of ZAP70, Src, EGFR and c-MET with 
phosphorylated Tyrosine (Y) residue shown in red 
ZAP70 TLNSDGYTPEPA 
Src RLIEDNEYTARQG 
EGFR SNESVDYRATFPE 
c-MET LQRYSSDPTGA 
 
 
 
 
Figure 5-3: Generation of Ub fusion peptides to function as substrates to 
elucidate RING-mediated substrate polyUbiquitination. (A) All Ub fusion 
constructs contain an N-terminal GST followed by Ub, a flexible linker (3GGS 
repeats) and a substrate peptide(ZAP70,Src,c-MET, EGFR). The TYR residue marked 
in red must be phosphorylated to bind to E3. There is a His tag at the C-terminus of 
each construct. (B) Desired E3-E2–Ub-substrate system with RING E3 bound to E2–
Ub and substrate (Ub fusion peptide).  
 
All the constructs were cloned into the vector pGEX-4T1, which contains an N-
terminal GST-tag followed by a thrombin cleavage site. We also inserted a 6xHis-tag 
at the C-terminus to facilitate purification. To phosphorylate the tyrosine on the 
substrate peptide, I co-expressed these constructs with His-MBP-tagged tyrosine 
kinases. It is noteworthy that these Ub-peptides only contain one tyrosine within the 
peptide sequence. This co-expression strategy has been previously used in our lab to 
generate tyrosine phosphorylated Cbl in E. coli [85]. Since I didn’t know which 
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kinase would phosphorylate these substrate peptides, I tried several kinases such as 
Src, ZAP70, Hck, Lck, Fyn and TKX1 that were available in the lab. 
 
5.2.2 Test expression and purification of Ub-peptides 
 I transformed Ub-fused ZAP70 peptide (Ub-ZAP70) together with ZAP70, Src, Hck, 
Fyn, Lck or TKX1 tyrosine kinase. Small-scale protein expression and purifications 
were performed (see Method Section 2.3) in these GST-tagged Ub-peptides were 
pulled down with GSH-sepharose and cleaved with thrombin. Following thrombin 
cleavage, bands corresponding to the size of Ub (~10 kDa) were present in GST-Ub-
ZAP70 co-expressed with ZAP70, Fyn, Lck and Src whereas co-expressions with Hck 
and TKX1 yielded bands of ~10 and 12 kDa that correspond to the predicated size of 
Ub and Ub-ZAP70 (~12 kDa), respectively. Notably, only a small fraction of the total 
protein corresponds to Ub-ZAP70.
 
Figure 5-4: Small-scale purifications of Ub-ZAP70 co-expressed with different 
kinases visualised by SDS-PAGE. Lane A indicates Ni2+ pull down and lane B 
subsequent thrombin cleavage for Ub-ZAP70 co-expressed with indicated tyrosine 
kinases. 
 
These bands were then subjected to analyses with mass spectrometry. Mass 
spectrometry analyses showed that lanes 4 and 8 contained a mixture of Ub-ZAP70 
and Ub. These findings were consistent with cleavage of Ub-ZAP70 just after the C-
terminal diglycine motif of the Ub moiety, thereby generating Ub rather than Ub-
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ZAP70. A literature search showed that E. coli contains protease(s) that can cleave Ub 
after the C-terminal diglycine motif and this cleavage is prevalent when Ub is fused to 
a peptide, but reduced when fused to a folded protein [158]. Several strategies were 
implemented previously to resolve this issue: (1) growing cells at lower temperature 
[158]; (2) shorter expression time (3 hours, not overnight); (3) addition of a proline 
residue immediately after Ub (the Ub-Proline bond is not cleaved by Ub-specific 
proteases [159]); and (4) replacing C-terminal Gly-Gly motif  with Ala-Ala or Ala-
Ala-Pro (Figure 5-5). 
 
 
Figure5-5: Trouble-shooting Ub-peptide cleavage in E. coli. (A) Design of Ub-
peptide. (B) Cleavage of Ub-peptide during protein expression. (C) Replacement of 
Ub’s C-terminal Gly-Gly motif with Gly-Gly-Pro. (D) Replacement Ub’s C-terminal 
Gly-Gly motif with Ala-Ala to overcome cleavage problem. 
 
Based on these findings, I re-engineered my Ub-ZAP70 by replacing Ub’s C-terminal 
Gly-Gly motif with Ala-Ala-Pro.  
 
5.2.3 Test expression and purification of re-engineered Ub fused 
peptide 
A small-scale protein expression and purification test was performed on co-
expressions of the newly designed Ub-ZAP70 with Ala-Ala-Pro substitution and 
various kinases in E. coli.  A new purification protocol was implemented to avoid 
pulling down Ub products in which the peptide fragment was cleaved. For these 
purifications, Ni2+-affinity chromatography was initially performed followed by 
thrombin cleavage and then GSH-sepharose chromatography to remove the GST tag 
(Figure 5-6). Strikingly, intact Ub-ZAP70 was recovered in every case. Thus, 
substitution of Ub’s C-terminal Gly-Gly motif with Ala-Ala-Pro resolved the 
cleavage issue.  
Next, to assess the phosphorylation status of Ub-ZAP70, I performed western blots 
using anti-phospho-tyrosine antibody on the products from the above purifications 
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and found that Ub-ZAP70 is only phosphorylated when co-expressed with Src kinase 
(Figure 5-7). Hence, I was successful in developing a method for expressing 
phosphorylated Ub-ZAP70 (Ub-ZAP70p). Next, I scaled up production of Ub-ZAP70 
and developed a method to separate phosphorylated (Ub-ZAP70p) and 
unphosphorylated Ub-ZAP70. In the remaining chapter, all Ub-peptide constructs 
contain a C-terminal Ala-Ala-Pro substitution in Ub. 
 
 
Figure 5-6: SDS-PAGE of Ub-ZAP70 with a C-terminal Ala-Ala-Pro substitution 
after Ni2+-affinity pull down and cleavage with thrombin. E. coli lysate was 
subjected to Ni2+-affinity purification and eluted product was loaded in lanes A and 
treated with thrombin followed by GSH-sepharose pass-back to remove GST-tag in 
lane B  
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Figure 5-7: Western Blot of purified Ub-ZAP70 from co-expressions with 
tyrosine kinases. Ub-ZAP70 containing a C-terminal Ala-Ala-Pro substitution in Ub 
was co-expressed with indicated kinases and purified as described in Figure 5-6.  
Purified samples were probed with anti-phospho-tyrosine antibody to determine 
which kinases phosphorylated Ub-ZAP70.   
 
5.2.4 Developing a method to separate tyrosine phosphorylated and 
unphosphorylated Ub-ZAP70  
As mentioned in section 5.2.3, I developed a method for generating phosphorylated 
Ub-ZAP70. Based on our experience in generating tyrosine phosphorylated Cbl [85], 
it is difficult to achieve 100% phosphorylation. Thus, it is important to separate 
phosphorylated Ub-ZAP70 from the unphosphorylated species. To achieve this, I 
used anion exchange chromatography. Following GSH-sepharose chromatography, 
protein was subsequently applied to a SourceQ column and eluted using a gradient of 
NaCl (Figure 5-8). Eluted fractions were loaded onto an SDS-PAGE gel and 
subsequently analysed by Coomassie staining (Figure 5-8B) or Western blot using an 
anti-phospho-tyrosine antibody (Figure 5-8C). Fractions that eluted at higher salt 
concentrations were phosphorylated whereas those that eluted as lower salt 
concentrations were not.  
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Figure 5-8: Separation of phosphorylated and unphosphorylated Ub-ZAP70. (A) 
Chromatogram obtained from anion exchange using a 20ml Source Q column. (B) 
SDS-PAGE separation and Coomassie stain of eluted fractions from (A) (Fractions 
A6, A7, B10, B9, B8 and B7). (C) Western blot of fractions from (B) probed with an 
anti-phospho-tyrosine antibody. Phosphorylated Ub-ZAP70 is indicated. 
 
Next, I re-engineered and purified phosphorylated Ub-fused Src peptide (Ub-Srcp) 
and Ub-fused c-Met peptide (Ub-Metp) using methods similar to those described in 
sections 5.2.3, 5.2.4 and 5.2.5. These three phosphorylated Ub-peptides were used in 
the subsequent experiments. 
5.2.5  Biochemical assay to validate Ub-ZAP70p as a substrate  
To validate whether Ub-ZAP70p acts as a ubiquitinated substrate mimetic for Cbl, I 
performed ubiquitination assays to assess whether activated c-Cbl (pCbl; c-Cbl 47-
435, Y368F, pY371; [85]) can transfer Ub to Ub-ZAP70p. pCbl only ubiquitinates 
Ub-ZAP70p but not its unphosphorylated counterpart. Thus, the interactions between 
Cbl and the phosphorylated ZAP70 moiety of Ub-ZAP70p presumably placed the Ub 
moiety proximal to the E2~Ub thioester bond, thereby enabling Ub-ZAP70p to 
function as a ubiquitinated substrate mimetic. 
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Next I wondered whether the length of the linker connecting Ub and ZAP70p 
influenced the efficiency of Ub transfer. Hence, I introduced various linker size 
sequences (no linker, 1, 3, and 5 Gly-Gly-Ser linkers) between Ub and ZAP70p and 
performed ubiquitination assay to assess the effect of the linker length on pCbl-
mediated Ub transfer. Ub-ZAP70p functioned as a substrate mimetic with all of these 
linkers, but multiple Ub transfers were only observed with no linker or with one Gly-
Gly-Ser linker (Figure 5-10). 
 
 
       
 
Figure 5-9: SDS-PAGE showing ubiquitination of Ub-ZAP70p catalysed by 
pCbl. Phosphorylated and unphosphorylated Ub-ZAP70p and ubiquitinated products 
are indicated. 
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Figure 5-10: SDS-PAGE showing ubiquitination of Ub-ZAP70p with varying 
linker lengths catalysed by pCbl. (A) Ubiquitination Ub-ZAP70p with no linker. (B) 
Ubiquitination Ub-ZAP70p with one Gly-Gly-Ser linker. (C) Ubiquitination Ub-
ZAP70p with three Gly-Gly-Ser linkers. (D) Ubiquitination Ub-ZAP70p with five 
Gly-Gly-Ser linkers.  
 
5.2.6 Assembling pCbl-E2–Ub complex bound to phosphorylated Ub-
peptides 
To investigate how Cbl promotes polyubiquitination, I wanted to elucidate a structure 
of a complex of my substrate mimetic bound to activated Cbl and E2–Ub. Previously, 
our lab determined structures of pCbl-b-UbcH5B–Ub-ZAP70 peptide complex and 
pCbl-UbcH5B–Ub-ZAP70 peptide[73]. In both of these complexes, the catalytic site 
of E2 faces ZAP70 peptide. Hence, I purified phosphorylated c-Cbl and Cbl-b 
variants by co-expressing them with Src kinase to generate activated Cbl (see 
Methods Section 2.4). For E2–Ub conjugates, a variety of stable E2–Ub complexes 
with an amide or oxyester bond were generated (see Methods Section 2.6). Using 
different combinations of phosphorylated Cbl, E2–Ub and phosphorylated Ub-
peptide, I setup crystallisation trials on various complexes as shown below.  
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5.2.6.1 pc-Cbl-UbcH5BS22R–Ub-Ub-3ggs-Srcp 
The first complex I assembled for crystallisation was pc-Cbl-UbcH5BS22R–Ub-Ub-
3ggs-Srcp. Previous studies have shown that the UbcH5 family has surface opposite 
the active site that binds Ub non-covalently and stimulates Ub transfer [36, 40]. To 
eliminate the possibility of the Ub moiety from Ub-3ggs-Srcp binding the backside of 
UbcH5B, I used UbcH5BS22R–Ub to generate my complex because this UbcH5B 
mutation prevents backside binding by Ub. The stock concentration of pc-Cbl, 
UbcH5BS22R–Ub, Ub-3ggs-Srcp was 8.5mg/ml, 24.5mg/ml and 19.5mg/ml 
respectively. We know from previous study the binding affinity of pc-Cbl to 
UbcH5B–Ub is very tight[73]. Hence I mixed the complex with molar ratio of 1:1:1.5 
pc-Cbl: UbcH5B–Ub-Ub-3ggs-Srcp, such that final concentration of pc-Cbl was 
approx. between 5.5-6mg/ml. I screened the complex for crystal formation using more 
than 1000 conditions at 19°C. After 48 hours, I obtained crystals in several 
conditions, most of which contained low percentage of PEG or AmSO4 as the 
precipitant (Figure 5-11A and B). I optimised both crystallisation conditions and ran 
crystals on an SDS-PAGE gel to confirm that all components of the protein complex 
were present in the crystals (Figure5-11D). Initially the crystals simply dissolved 
upon adding cryoprotectant such 20% ethylene glycol, MPD or glycerol. I then had to 
screen lot of cryoprotectants to find a condition where my crystals did not dissolve. I 
tried a series of cryoprotectants like glucose, sucrose, xylitol, MPD, several low 
molecular weight PEGS and found that 20% sucrose worked best as a cryoprotectant 
for my crystals. After, I overcame the dissolving issues, I tested the diffraction quality 
of my crystals. Unfortunately, crystals grown in AmSO4 conditions did not diffract at 
all. I then optimised growth conditions for crystals using PEG as a precipitant. 
Despite using a variety of different cryoprotectants/techniques and regardless of my 
crystallisation conditions, the highest resolution diffraction I obtained was 6 Å. This 
included test shots of my crystals at room temperature in the absence of any 
cryoprotectant. Nonetheless, the diffracted crystals were indexed and assigned to the 
space group P 21 21 2 with the following unit cell dimensions:  a=127.9, b= 286.78, 
c= 60.48, α=β=γ=90° 
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Figure 5-11: Results from crystallisation experiments obtained from Table 5.2. 
(A) Crystals of pCbl-UbcH5BS22R–Ub-Ub-Srcp grown in 1.6 M AmSO4 and 0.1 M 
Tris-HCl 8.5. (B) Crystals of pCbl-UbcH5B S22R–Ub-Ub-Srcp grown in 5.5% 
PEG3350 0.1 M MES 6.5. (C) Crystals of pc-Cbl-UbcH5B–Ub-Ub-ZAP70p-Ub 
grown in 20 %(v/v) ethylene glycol, 10 %(v/v) PEG8K, 0.1M Tris HCl pH 8.5. (D) 
SDS-PAGE showing the protein components of the crystals in (A), (B) and (C) as 
indicated (just put A, B, C over the lanes instead).  
 
5.2.6.2 pc-Cbl-UbcH5BC85K–Ub-Ub-3ggs-Srcp with free Ub 
Since crystals from pc-Cbl-UbcH5BS22R–Ub-Ub-3ggs-Srcp complex diffracted 
poorly, I decided to set up alternative complexes that might involve different crystal 
packing. To do this, I decided to use UbcH5BC85K–Ub (UbcH5B’s active Cy85 
mutated to lys85 to generate a stable isopeptide linkage)[66]. I also added free Ub to 
saturate UbcH5B’s backside surface. The stock concentration of pc-Cbl was same as 
described above, whereas UbcH5BC85K–Ub, Ub-3ggs-Srcp and Ub were at 
22.5mg/ml, 19.5mg/ml and 100 mg/ml respectively. I mixed the complex pc-Cbl-
UbcH5BC85K–Ub-Ub-3ggs-Srcp-Ub in  1:1:1.5:1 molar ratio, such that final 
concentration of the complex was approx. between 7-8 mg/ml. I screened the complex 
with and without free Ub for crystal formation in over 1000 conditions. I only 
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observed crystal formation for complex containing free Ub in similar conditions to 
pc-Cbl-UbcH5BS22R–Ub-Ub-3ggs-Srcp complex, that is in low PEG and low AmSO4 
conditions, but these crystals did not diffract any better than what I had earlier, even 
after optimisation. 
 
5.2.6.3 pc-Cbl-UbcH5B–Ub-Ub-3ggs-ZAP70p 
Alternatively, I also set up complex with another substrate mimetic, Ub-3ggs-ZAP70. 
This time I screened complex with UbcH5BS22R–Ub or UbcH5BC85K–Ub in two 
separate drops on the same plate. Crystallisation screening and complex set up was 
the same as mentioned above in the previous crystallisation experiments. Crystals 
obtained are shown in figure 5-11C. I again observed numerous crystal hits in 
conditions containing low PEG, low pH and glycerol, but they all diffracted poorly. 
 
5.2.6.4 Other E3-E2–Ub-substrate complex 
After my initial crystallisation attempts to obtain high-resolution crystallisation data 
failed, I used a different strategy to generate a complex. I made modifications to my 
substrate, used different E2–Ub and tried alternative E3s. These strategies are 
discussed briefly below. Additionally, these alternative complexes are listed in Table 
5-2. 
Substrate: As shown in Figure 5-10, substrate mimetics with smaller linkers or 
lacking linker are more active in ubiquitination. Therefore, I used Ub-ZAP70p, Ub-
Srcp, Ub-ggs-ZAP70p, and Ub-ggs-Srcp for additional crystallisation trials. I thought 
that a longer linker might be more flexible and contribute to conformational 
variability. To eliminate flexibility and to try and capture a more restrained complex, I 
set up screens with pc-Cbl-E2–Ub and ZAP70p or Srcp with no linker or 1ggs linker. 
I obtained crystals of these complexes but the diffraction quality did not improve. 
E2–Ub: Initially I used UbcH5BS22R–Ub and UbcH5BC85K–Ub in my crystallisation 
complexes for reasons explained above. Because all my crystals with UbcH5B 
diffracted poorly, I decided to try another E2. UbcH5B has the ability to make a 
variety of polyUb chains and is very promiscuous [160]. I thought this might 
contribute to  the poor diffraction . Therefore I chose UbcH6, which makes lys48-
specific chains. I set up complex with UbcH6C131K,S68R–Ub, which was cloned, 
expressed and purified by my supervisor Danny Huang. For this E2–Ub, the catalytic 
	 132	
cys is mutated to lys (C131K) to generate a stable isopeptide linkage and S68R 
abrogates backside binding to Ub. Unfortunately I did not get any crystal hits from 
complex containing UbcH6C131K,S68R–Ub. 
E3: I used pc-Cbl for all my initial crystallisation experiments. When none of the 
complexes with pc-Cbl diffracted to high resolution, I decided to use pCbl-b. I set up 
the following complexes with pCbl-b: pCblb-UbcH5BS22R–Ub-Ub-1ggs-Srcp, pCblb-
UbcH5BC85K–Ub-Ub-1ggs-ZAP70p-Ub, pCblb-UbcH6C131k,S68R–Ub-Ub-1ggs-Srcp 
and pCbl-b- UbcH6C131k,S68R–Ub- Ub-1ggs-ZAP70p. I obtained crystals of all of these 
complexes except UbcH6–Ub; as observed with pc-Cbl, all the crystals diffracted 
poorly .  
 
Table: 5-2 E3-E2–Ub-Ub-peptide complexes used for crystalisation trials 
E3 E2~Ub Substrate Concentration 
(mg/ml) 
pc-Cbl UbcH5BC85K,S22R–Ub Ub-3ggs-ZAP70 ~7.5 
pc-Cbl UbcH5BC85K,S22R–Ub Ub-3ggs-Src ~7.0 
pc-Cbl UbcH5BC85K–Ub Ub-3ggs-ZAP70 ~7.0 
pc-Cbl UbcH5BC85K–Ub Ub-3ggs-Src ~7.5 
pCbl-b UbcH5BC85K,S22R–Ub Ub-3ggs-ZAP70 ~8.0 
pCbl-b UbcH5BC85K,S22R–Ub Ub-3ggs-Src ~8.0 
pCbl-b UbcH5BC85K,S22R–Ub Ub-1ggs-ZAP70 ~7.0 
pCbl-b UbcH5BC85K,S22R–Ub Ub-1-ggs-Src ~7.5 
pCbl-b UbcH6C131K, S68R–Ub Ub-1ggs-Src ~7.5 
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5.3 Discussion 
Zheng et al., (2000) determined the first structure of a RING E3 bound to an E2: the 
N-terminal fragment of c-Cbl bound to UbcH7 and a peptide fragment of the substrate 
ZAP70. In this structure, ZAP70 peptide and E2’s catalytic Cys are separated by 67 Å 
(Figure 5-1A). Subsequently our lab showed that phosphorylation of a conserved 
tyrosine in Cbl’s LH induces conformational changes that juxtapose E2’s catalytic 
Cys and the substrate-binding site (Dou et al., in 2012), leaving a gap between E2’s 
catalytic Cys and ZAP70 peptide of about 27 Å (Figure 5-1B). In these structural 
studies, the ZAP70 peptide fragment lacks lysine residues and therefore cannot be 
ubiquitinated. It seems likely that a longer fragment of substrate or a full-length 
substrate could bridge such gap. At the start of my PhD, Danny had designed Ub-
peptides to mimic ubiquitinated substrate to enable studies of the mechanism of poly 
Ub chain formation. Modelling studies suggested that the 27-Å gap between E2’s 
catalytic Cys and ZAP70 peptide in the structure could be bridged by an Ub moiety. 
Thus the goal of my project was to develop and optimise methods to generate Ub-
peptide substrate mimetics for biochemical analyses and structural determination. 
Generation of Ub-peptide was challenging in the beginning. Initially, Ub-ZAP70 was 
cleaved following the C-terminal diglycine motif in Ub; hence, Ub was purified rather 
than Ub-ZAP70   (Figure 5-5 and section 5.2.2). I then re-engineered the construct to 
overcome the cleavage problem by replacing the diglycine motif at the C-terminus of 
Ub with a dialanine motif and introducing a proline residue (See section 5.2.2). This 
solved the cleavage issue and I was able to obtain Ub-ZAP70 (Section 5.2.2, Figure 5-
7). The next challenge was to determine which kinase could phosphorylate Ub-
ZAP70 and how to separate the phosphorylated and unphosphorylated Ub-ZAP70. I 
showed that Src kinase phosphorylates Ub-ZAP70 and other Ub-peptides. To separate 
the phosphorylated and unphosphorylated Ub-ZAP70, I developed a method using 
anion exchange chromatography to separate the two species (Section 5.2.4, Figure 5-
4). Next, I performed ubiquitination assays to determine if Ub-ZAP70p is 
ubiquitinated by pCbl. (Section 5.2.5, Figure 5.9). Indeed, I showed that Ub-ZAP70p 
was ubiquitinated readily by pCbl whereas the unphosphorylated Ub-ZAP70 was not. 
These results showed the suitability of our model suitable for studying the mechanism 
of RING E3-catalysed polyUb chain formation. 
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I then setup various complexes of pCbl bound to E2–Ub and phosphorylated Ub-
peptide (Section 5.2.6). Most of my crystallisation experiments yielded crystal hits 
(Figure 5-11) but the diffraction quality of these crystals was poor. I then used various 
methods like crystal dehydration and growing complex in different conditions to 
improve diffraction quality.. The highest quality diffraction I obtained was 6 Å. Since 
I could not improve the diffraction resolution of my complex, I then started setting up 
complex with Cbl-b, additional E2–Ub variants and other phosphorylated Ub-peptides 
that I generated (Table 5-2). Although I obtained crystals for many of these 
complexes, none diffracted better than my earliest crystals. I also wondered if the 
length of linker in between my fusion peptide might be too flexible and hence the Ub 
moiety in the phosphorylated Ub-peptide is loosely packed. I generated linker of 
varying lengths, all tested previously with ubiquitination assay to be optimal to act as 
substrate mimetic (Figure 5-10). I set up crystallisation trials with phosphorylated Ub-
peptides with varying lengths, but still did not improve the diffraction. 
Unfortunately, I was unable to obtain crystals of suitable diffraction quality to gain 
insights into how these components pack together and to assess whether we could 
capture E2~Ub bound to acceptor Ub at the E2’s active site (a transient event in Ub 
transfer) using this strategy. During my PhD, Christopher Lima’s group published a 
structure of SUMO E3, Siz1, bound to Ubc9–SUMO and a substrate, PCNA where 
they use a chemical crosslinking strategy to link PCNA’s Lys164 to Ubc9’s catalytic 
cysteine [161]. This strategy reduces conformational flexibility and eliminates 
potential non-specific protein-protein packing arrangement during protein 
crystallisation and would be worth investigating in the context of an E3-E2~Ub-Ub-
substrate complex. Another possibility is to capture full-length substrate in complex 
with E3-E2~Ub instead of peptide which can be too flexible or too short to reach E2’s 
active site. Of course all of these alternatives are equally challenging and will require 
great precision and biochemical understanding to capture E3-E2~Ub-substrate 
complex. 
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6. Conclusions and future work 
6.1 Uncovering mechanisms of non-covalent binding of Ub in other E3s and E2s 
My structure of cIAP1R with UbcH5B–Ub shows how the C-terminal tail of cIAP1 
locks UbcH5B–Ub in a closed conformation primed for Ub transfer (chapter 3). Apart 
from RING E3s stabilising E2~Ub, there are various other components that provide 
further stability to the complex. One such component is non-covalent binding of Ub 
to the backside of the UbcH5 family of E2s. It is now evident that the mechanism of 
non-covalent binding of Ub increases the processivity of E2~Ub transfer in the 
UbcH5 family of E2s by stabilising the E3-E2~Ub complex. Crystal structures of the 
monomeric RING E3 RNF38 with UbcH5B–Ub and UbB [40] and dimeric RING 
cIAP1 bound to UbcH5B–Ub and UbB (chapter 3) both showed that the α1β1 loop of 
UbcH5B is oriented in the presence of UbB in a conformation that helps to further 
stabilise the donor Ub in a primed conformation in the complex. The mechanism 
seems to be conserved across RING E3s, but whether this mechanism is conserved in 
other E2 families needs to be further investigated. 
To address the role of UbB in other E2s, I studied the core domain of UbcH6 (chapter 
4). The backside surface of UbcH6 is very similar to that of the UbcH5 family, but a 
previous study reported that UbcH6 lacks backside binding of Ub. Contrary to this 
previous studies, my results showed that non-covalent binding of Ub does stimulate 
UbcH6. However, my results showed that  UbB binds UbcH6 more weakly than 
members of the UbcH5 family. My results also suggest that the mechanism of 
stimulation in UbcH6 differs than that observed in the UbcH5 family. This opens up 
new opportunities for investigating UbB mechanisms in other E2s. In addition, it will 
also be interesting to study full length UbcH6 and determine whether the regions 
outside of the core domain of the E2 affect non-covalent binding of Ub since the 
estimated affinity of UbB to the core domain of UbcH6 is higher than 1 mM. Together 
my results from chapters 3 and 4 suggest that there is more to the UbB mechanism that 
is not yet fully understood and requires further investigation. It is very interesting to 
see how two different families of E2s, which share similar UBC domains, have 
different mechanisms for UbB stimulation. This has opened new opportunities for 
studies in the field of E2 backside stimulation. This is the second structural and 
biochemical report of a UbB mechanism following that of Buetow et al. in 2015, and 
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it will be interesting to determine how it functions in cells and characterise its 
mechanism of action.  
6.2 Generation of substrate mimetics to study polyUb chain formation 
How RING E3s promote Ub transfer from E2~Ub to a lysine residue in substrate 
remains elusive. To understand the mechanism of polyUb chain formation, I 
generated several Ub-substrate mimetics to investigate how c-Cbl primes E2~Ub and 
ubiquitinated substrate to catalyse polyUb chain formation (chapter 5). I hypothesised 
that Ub-fused substrate peptide would be in close proximity of the thioester in E2~Ub 
and could function as an acceptor for studying polyUb chain formation. Biochemical 
studies showed that my substrate mimetics underwent ubiquitination. I assembled 
various Cbl-E2~Ub complexes bound to Ub-fused peptide and attempted to crystallise 
these complex to understand the mechanism of RING E3-catalysed polyUb chain 
formation. Unfortunately none of my crystals diffracted better than 6Å. Capturing an 
E3-E2~Ub-substrate complex is not trivial. During my PhD, I tried several 
optimisation techniques to get higher resolution diffraction, but none of them gave me 
resolution of sufficient quality to determine a structure. There are various factors that 
might contribute to the poor diffraction quality of my complexes including 
conformational flexibility, low binding affinities and lack of specificity. To eliminate 
these factors, future work could include using a full-length substrate to study the 
complex. Other techniques like chemical cross-linking to cross-link E2’s active site to 
substrate might also be beneficial; this technique will restrict the conformational 
flexibility within the complex and might help in the crystal packing arrangement. 
 
6.3 Characterisation of IAPs and Cbls 
 The IAP family of proteins play a significant role in many cellular processes 
including cell death and survival. Currently, there are no full length crystal structures 
of any member of the IAP family of proteins, hence we still do not completely 
understand their regulatory mechanisms. The longest structure available is that of 
cIAP1 extending from the BIR3 domain to the C-terminus; this structure reveals that 
cIAP1 is in an autoinhibited conformation in which it exists as a monomer. Upon 
binding SMAC or caspases, cIAP1 undergoes conformational changes in which it 
forms a RING-mediated dimer and undergoes autoubiquitination [139]. 
Overexpression of IAPs has been linked to tumour growth and poor prognosis for 
several types of cancer. Recently, SMAC mimetics that target IAP BIR domains have 
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emerged as a promising platform in the development of anticancer therapeutics [162]. 
Athough IAPs are recognised as favourable drug target, how they are regulated still 
remains elusive and merits further investigation.. 
Cbls act as adaptor proteins and as E3 ubiquitin ligases. The latter function plays an 
important role in ubiquitination of RTKs. Based on its different functions in 
regulating immune response and development of cancer, they have emerged as a new 
class of therapeutic targets [163]. Certain mutations in Cbls lead to loss of E3 ligase 
activity. For example, mutation of Y371, which undergoes phosphorylation and 
activates Cbls’ E3 ligase activity, is frequently found in patients with leukemia. In this 
case, development of drugs that can mimic the phosphorylated tyrosine can provide 
new therapeutic opportunities. 
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